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ABSTRACT 
 
Cancer is a leading cause of death worldwide as cancer cells have the ability to 
develop resistance to chemotherapeutic agents due to their high expressions of 
resistance gene. More research on alternative strategies to eradicate this type of 
malignant cells is highly desired by using natural products with fewer side effects. 
This study initially investigates the cytotoxicity of 20 novel semi-synthetic 
cardamonin derivatives and complexes in A549 lung and HK1 nasopharyngeal cancer 
cell lines. Structure activity relationship analysis revealed the factors affecting 
cytotoxicity were modification of hydroxyl group, presence of alkene group, addition 
of chemical groups, with the greatest cytotoxicity advantage being complexing with 
metal ions. Cardamonin-Cu(II) and cardamonin-Fe(II) complexes were determined as 
the two most cytotoxic compounds and were selected for further cytotoxic analysis in 
normal MRC5 lung and normal Hs68 foreskin cell lines. Results showed toxicity in 
MRC5 lung cells but was less toxic in Hs68 foreskin cells, suggesting some level of 
selectivity from cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) depending on 
the type of cells exposed to. Subsequently, cardamonin and its two complexes were 
tested in Jurkat T leukaemic cells and results showed highest susceptibility in this 
leukaemic cell line prompting further investigation on differential susceptibility of 
adherent and suspension cells. THP-1 monocytic leukaemia cell line cultured in both 
suspension and adherent phase demonstrated increased resistance in THP-1-derived 
macrophages in adherent phase compared to THP-1 monocytes in suspension form. 
Herein, we investigated the effects of interference from inhibitors of p38α and p38β 
MAP kinase and found THP-1-derived macrophages’ increased resistant towards 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes were independent 
of p38α and p38β MAP kinase pathway. As Jurkat T cells exhibited lowest IC50 
values in cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II)-treated cells, we 
next explored the underlying mechanism of action in this cell. All three compounds 
were found to induce apoptotic cell death via the intrinsic mitochondrial pathway in 
Jurkat T cells as evidenced by the morphological changes, phosphatidylserine 
externalisation, caspase-3, -9 and PARP-1 cleavage, and collapse of mitochondrial 
membrane potential. Caspase-8, an initiator caspase of the extrinsic pathway was not 
activated. The presence of a caspase inhibitor, Z-VAD-FMK, was able to inhibit 
caspase processing and block cell death, further confirming the induced apoptotic cell 
death was caspase-dependent. As previous studies have reported the ability of metals 
to induce apoptosis through oxidative stress, the effects of these three compounds on 
reactive oxygen species (ROS) generation and intracellular glutathione (GSH) levels 
were explored. Results revealed cardamonin and cardamonin-Fe(II)-induced depletion 
of intracellular GSH and production of ROS; whereas cardamonin-Cu(II) did not 
significantly affect intracellular GSH levels but generated ROS. The presence of low 
molecular weight thiols, N-acetylcysteine (NAC), L-cysteine and GSH as well as 
Trolox, a ROS scavenger, blocked cardamonin and cardamonin-Fe(II)-induced Jurkat 
T cell death, while D-cysteine, which cannot be metabolised to GSH had no effect. 
However, these low molecular weight thiols had no effect on cardamonin-Cu(II)-
treated cells with the exception of Trolox, confirming the role of ROS in cardamonin-
Cu(II)-induced Jurkat T cell death. Furthermore, intracellular ROS and GSH levels 
were recovered close to levels of untreated Jurkat T cells in the presence of Z-VAD-
FMK. In conclusion, this study demonstrates cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) induced apoptotic cell death in Jurkat T cells via an oxidative 
stress mediated intrinsic mitochondrial pathway that was caspase-dependent. 
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CHAPTER 1: INTRODUCTION 
  
2 
 
1.1 Cell death mechanism 
 
In response to cytotoxic stimuli, cell death can occur either through apoptotic or 
necrotic cell death. Identifying the cell death pathway provides important clues for 
designing and improving therapeutic approaches.  
 
1.1.1 Apoptosis  
  
One of the main targets for anti-cancer therapy is the induction of cell apoptosis, 
programmed cell death (Denicourt and Dowdy 2004). External signals generated in 
the mitochondria or propagated within cells by receptors in the plasma membrane 
trigger apoptosis. These pathways that trigger apoptosis involve the activation of 
caspases, which are previously dormant cysteine-proteases (Llado et al. 2008). 
Initiator caspases are the first caspases activated by cell death signals. Depending on 
the apoptotic pathway used, initiator caspase-8 is associated with the extrinsic 
pathway while caspase-9 is associated with the intrinsic mitochondrial pathway (Basu 
et al. 2006). These proteins that undergo proteolysis subsequently activate effector 
caspases, caspase-3, -6 and -7, which when activated results in the cleavage of 
multiple target proteins (Haupt 2003). Some morphological and functional changes 
identified during an apoptotic process have been characterised including the changes 
in cell membrane, mitochondrial dysfunction, and changes in cell nucleus (Geske and 
Gerschenson 2001). The cell membrane of apoptotic cells externalise 
phosphatidylserine (PS) to the outer cell membrane to trigger the removal of apoptotic 
cells by phagocytic cells via PS recognition (Krahling et al. 1999). During an 
apoptotic event, the opening of the permeable transition pore disrupts the 
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mitochondrial inner transmembrane potential (Green and Kroemer 1998) leading to 
the release of pro-apoptotic protein known as apoptosis-inducing factor. This protein 
induces DNA fragmentation and apoptosis by the activation of endonucleases (Susin 
et al. 1997). The morphology of dying cell undergoes rapid changes such as nucleus 
and chromatin condensation, cell shrinkage, nuclear fragmentation, as well as 
blebbing of the plasma membrane. Subsequently, cell breaks up into apoptotic bodies, 
which are membrane-enclosed fragments. These apoptotic bodies are recognised and 
engulfed by macrophages or neighbouring cells rapidly (Orrenius et al. 2011). 
 
1.1.1.1 Morphological changes 
 
Based on morphological grounds, Kerr et al. (1972) established the concept of cell 
death as a process of disposing unwanted cells during normal cell turnover in 
proliferating tissues, embryonic development and pathological situations. ‘Apoptosis’ 
was the term coined by these investigators to describe this form of cell death and has 
since found wide acceptance. Cells dying via apoptosis in general displays a very 
uniform pattern of morphological changes (Häcker 2000). Apoptosis can often be 
detected easily under the microscope. Various changes can be observed by light 
microscope and sometimes with the aid of specific dyes. However, certain changes 
such as the loss of microvilli, changes to organelles, mitochondria swelling or 
condensation as well as dilatation of the endoplasmic reticulum can only be detected 
by electron microscope. A dying cell, as observed by light microscopy, starts to show 
protrusions from the plasma membrane, known as “blebs” or cell “blebbling”. Blebs 
form when pressure is generated by actomyosin contraction. Proteins that are 
recruited to bleb membranes give rise to bleb contractions and retractions (Julian and 
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Olson 2015). Cells stained with DNA dyes allow direct observation of the cell 
nucleus condensation. Prominent morphological changes in apoptosis are most 
notable on the cell nucleus. Dying cells stained with DNA dye often display 
condensed ring/ sphere along the nuclear envelope in the beginning. The dye will 
continue to extend to encompass the entire nucleus of the dying cell. Subsequently, 
the condensed nucleus starts to sever attachments to disassemble into several 
fragments. Consequently, the entire cell condenses and reorganises into apoptotic 
bodies that are membrane-bound vesicles made up of cytosolic elements, parts of 
condensed nuclei or organelles in various combination containing the contents of the 
cell (Kerr et al. 1972, Häcker 2000, Ziegler and Groscurth 2004, Elmore 2007). These 
morphological changes during apoptosis are demonstrated in Figure 1.1 as a 
schematic representation.  
 
 
Figure 1.1 Schematic representations of morphological changes during apoptotic 
cell death at various stages from left to right.  
Initial changes involved nuclear chromatin condensation along the perimeter of the 
cell nucleus and protrusion of the plasma membrane (A), as indicated by arrows. 
Blebbing of the cell starts to appear as the nucleus continues to condense completely 
and the cell shrinks (B). The nucleus segregates into several fragments while the 
organelles generally stays intact. During the late stages of apoptosis, cell disintegrates 
into apoptotic bodies that contain any parts of the cellular material (C). Finally, 
apoptotic bodies are taken up and digested by other cells via a lysosomal pathway. 
Figure adapted from Häcker (2000). 
 
A B C 
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1.1.1.2 Phosphatidylserine externalisation 
 
In normal cell membranes, the active maintenance of membrane phospholipid 
asymmetry is universal. Subsequent disruption with externalisation of PS is therefore 
a hallmark of apoptotic cells (Kagan et al. 2000). Studies have shown that the 
externalisation of PS serves as a vital signal for cell targeting and elimination of 
apoptotic cells by macrophages (Fadok et al. 1992, Savill et al. 1993, Savill 1997). 
The process of apoptosis includes important changes to the apoptotic cell membrane. 
The typical feature of eukaryotic cells’ plasma membrane is asymmetric distribution 
of lipids between the outer and inner leaflet where phosphatidylcholine and 
sphingomyelin are predominantly presented on the outer leaflet. On the other hand, 
PS, phosphatidylethanolamine and phosphatidylinositol are confined to the inner 
leaflet of the membrane (Leventis and Grinstein 2010). During apoptosis, the plasma 
membrane loses its lipid asymmetry and extracellular exposure of PS increases 
(Bevers and Williamson 2010). Figure 1.2 displays the common feature of plasma 
membrane in normal eukaryotic cells, and the changes to PS exposure during 
apoptosis. 
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Figure 1.2 Phosphatidylserine exposure during apoptotic cell death.  
Plasma membrane of normal eukaryotic cells (A) and plasma membrane of apoptotic 
eukaryotic cells (B). PC indicates phosphatidylcholine; PE indicates 
phosphatidylethanolamine; PI indicates phosphatidylinositol; PS indicates 
phosphatidylserine; and SM indicates sphingomyelin. Figure adapted from Julian and 
Olson (2015). 
 
 Translocation of PS to the external cell surface can be used as a sensitive 
probe to detect apoptosis. However, it is important to note that translocation of this 
phosphoprotein is not unique to apoptosis and occurs during cell necrosis. The major 
difference between apoptotic and necrotic cells is that immediately necrosis occurs, 
the cell membrane looses its integrity, while the cell membrane undergoing initial 
stages of apoptosis will remain intact. Therefore, the detection of externalised PS 
using a staining agent with an additional dye exclusion test of the cell membrane 
integrity allow discrimination between normal, early apoptotic, late apoptotic or 
necrotic cells (Vermes et al. 1995).  
A 
B 
Inner leaflet 
Outer leaflet 
Inner leaflet 
Outer leaflet 
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1.1.1.3 Mitochondrial membrane potential 
 
Apart from being the source of energy in supporting life under aerobic conditions, the 
mitochondria is also the source of initiation in apoptotic cell death signaling pathway 
(Gottlieb 2000). Numerous studies have established that apoptotic cell death is related 
to mitochondrial membrane potential (MMP), typically for cancer cells (Scarlett et al. 
2000, Hu and Kavanagh 2003). Mitochondrial regulation of apoptosis can be 
described at various levels including maintenance of ATP production (Leist and 
Nicotera 1997), regulation of MMP, as well as control of mitochondrial membrane 
permeability from the release of apoptogenic factors (Zoratti and Szabò 1996, Green 
and Kroemer 1998, Kroemer and Reed 2000). The inner membrane is highly resistant 
to proton leakage that leads to significant buildup of membrane potential. The 
decrease in MMP is known to cause activation of mitochondrial pro-apoptotic factors 
(Gottlieb 2000). Primarily, the mitochondrial inner membrane is rich of negatively 
charged glycoprotein giving the inner membrane a negatively charged potential. The 
presence of large proton acumination outside the inner membrane result in the 
transmembrane potential between the mitochondrial membrane. Hence, the loss of 
MMP balance can be detected using permeable cationic dyes that have the ability to 
enter the mitochondria based on the highly negative mitochondrial potential. The 
depolarisation of MMP leads to loss of the cationic dye intensity indicating cells 
undergoing apoptotic cell death. 
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1.1.1.4 Caspases 
 
Caspases are key effector molecules of apoptosis that exist mostly as inactive 
precursors. These effector molecules kill the cell once activated, playing a major role 
in the execution of apoptotic cell death. A total of 14 caspases, caspase-1 to caspase-
14, have been identified in mammalian cells with all expressed in human except 
caspase -11, -12 and -13 (Yan and Shi 2005). These caspases are divided into three 
groups depending on the function and homology. These include initiator caspases (-2, 
-8, -9 and -10), effector caspases (-3, -6 and -7) and inflammatory mediator caspases 
(-1, -4, -5, -11, -12, -13 and -14) (Zimmermann et al. 2001). Initiator caspases in 
general works upstream of the effector caspases where activation of initiator caspases 
induce apoptotic signals by cleaving effector caspases. Activation of effector caspases 
leads to cleavage of essential proteins in the cells. The cleavage of cell chromatin 
(Margolin et al. 1997) and protein, that supports the cell nuclear membrane, leads to 
dismantling of cell nucleus (Nicholson and Thornberry 1997). 
 
 Two main pathways that activate caspases are the extrinsic and intrinsic 
pathways. Extrinsic pathway is activated due to receptor-mediated signalling such as 
binding of the Fas ligand leading to recruitment of FAS-associated death domain 
protein (FADD). The recruitment of FADD activates caspase-8, which cleaves 
executioner caspase-3 and -7 causing apoptosis as shown in Figure 1.3A (Hengartner 
2000). Intrinsic pathway is activated by intracellular stress including cytotoxic drugs, 
radiation and nutrient starvation (Boatright and Salvesen 2003) and involves 
activation of B cell lymphoma 2 (BCL-2) family proteins (Hipfner and Cohen 2004, 
Julian and Olson 2015). Activated BCL-2 homology 3 (BH3)-only proteins leads to 
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BCL-2 antagonist (BAK) and BCL-2 associated X proteins (BAX) activation and 
mitochondrial outer membrane permealisation. The permealisation of the membrane 
leads to the release of proteins that promote caspase activation. The release of 
cytochrome c binds to apoptotic protease-activating factor 1 (APAF1) and forms 
apoptosome, which recruits and activates the initiator caspase-9 as shown in Figure 
1.3B. The activation of caspase-9 further leads to the cleavage of executioner 
caspases, such as caspase-3 and -7, subsequently activating apoptosis (Tait and Green 
2010).  
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Figure 1.3 Activation of caspase cascade and simplified model of intrinsic and 
extrinsic apoptotic pathways.  
Extrinsic pathway activated by receptor-mediated signalling such as binding of the 
Fas ligand and activation of initiator caspase-8 of the extrinsic pathway (A). Intrinsic 
pathway activated by intracellular stress stimulating BCL-2 family protein activation 
and mitochondrial outer membrane permeabilisation and release of cytochrome c that 
binds to APAF1 to form apoptosome and activation of caspase-9 (B). Figure adapted 
from Hipfner and Cohen (2004) and Julian and Olson (2015). 
 
 
 
 
 
(A) Extrinsic (B) Intrinsic 
Apoptosis 
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1.1.1.5 Caspase inhibitors 
 
Activation of caspases is controlled by a variety of inhibitors which interact directly 
with the protease (Ekert et al. 1999). There are several types of caspase inhibitors 
available commercially including Z-VAD-FMK that works by inhibiting the 
activation of initiator or effector caspases. This peptide caspase inhibitor has been 
shown to block caspase activity in vitro with inhibitory constant at low nanomolar 
range. Table 1.1 presents the research carried out by Garcia-Calvo et al. (1998) 
reporting the inhibitory constant of Z-VAD-FMK caspase inhibitor for mammalian 
caspases and the function of different caspases in mammals. Z-VAD-FMK was 
originally developed for therapeutic uses but unforeseen cytotoxicity of this 
compound limited its potential as a drug. However, to date, Z-VAD-FMK remains a 
key compound for studies on apoptosis (Van Noorden 2001).  
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Table 1.1 Inhibitory constant of Z-VAD-FMK caspase inhibitor for mammalian 
caspases and caspases function. 
Caspases Z-VAD-FMK inhibitory 
constant expressed as t1/2* at  
1 µM in seconds 
Key Function 
Caspase 1 2.5 Inflammation 
Caspase 2 2400 Less easily categorised 
Caspase 3 43 Apoptosis - executioner caspase 
Caspase 4 130 Inflammation 
Caspase 5 5.3 Inflammation 
Caspase 6 98 Apoptosis – Executioner caspases 
Caspase 7 39 Apoptosis – Executioner caspases 
Caspase 8 2.5 Apoptosis – Initiator caspase 
(Extrinsic pathway) 
Caspase 9 3.9 Apoptosis – Initiator caspase 
(Intrinsic pathway) 
*Half-life (t1/2) is the time required for the concentration to fall to 50% of its current 
value. Information gathered from (Garcia-Calvo et al. 1998, Ekert et al. 1999, Van 
Noorden 2001, Mcllwain et al. 2013). 
 
1.1.2 Necrosis 
 
Necrosis is a very rapid form of cell death where every compartment of the cell 
disintegrates. Essentially, necrotic cell death is characterised by ion homeostasis 
dysregulation leading to dilation of endoplasmic reticulum and mitochondria, cell 
swelling and vacuoles formation in the cytoplasm. Contrary to apoptosis where 
caspases play a major role, lysosomal proteases mainly cathepsins B and D are mainly 
involved in necrosis. During necrosis, caspases may be activated due to cytochrome c 
release and mitochondrial damage but are not essential for cell death. During necrosis, 
chromatin forms clumps and the nuclear membrane disrupts. Cell lyses lead to the 
release of cell contents into the extracellular content where neighbouring cells may be 
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damaged and triggers an inflammatory response. In cells undergoing necrosis, ATP 
levels are depleted rapidly and the protein synthesis and genes transcription stops 
(Mattson and Bazan 2012). 
 
1.2 Oxidative-stress-induced cell death 
 
An appropriate balance in anti-oxidants and oxidants is required for the survival of 
mammalians cells (Buttke and Sandstrom 1994). Reactive oxidants encountered by 
organismal life are generated from internal metabolism and/ or exposure to 
environmental toxicants (Ma 2013). Buttke and Sandstrom (1994) suggested that 
mammalian cells actually benefit from this perilous existence mediating apoptosis by 
triggering oxidative stress. The authors reported that the depletion of cellular anti-
oxidants or addition of reactive oxygen species (ROS) could result in apoptosis that is 
necessary for aerobic life and that oxidative stress mediated-apoptosis can be blocked 
by addition of compounds with anti-oxidant capabilities.  
 
1.2.1 Reactive oxygen species 
 
ROS can be divided into two groups: free radicals and non-radicals. Molecules of one 
or more unpaired electrons are free radicals, which give reactivity to the molecules. 
Non-radical forms are created when two free radicals share their unpaired electrons. 
The three main physiological significant ROS include superoxide anion (O2
•-), 
hydroxyl radical (•OH), and hydrogen peroxide (H2O2) (Birben et al. 2012). Many 
studies have demonstrated that ROS and the resulting oxidative stress play a pivotal 
role in apoptosis (Forrest et al. 1994, Slater et al. 1995, Clutton 1997, Chandra et al. 
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2000, Kannan and Jain 2000, Curtin et al. 2002, Ozben 2007, Franco et al. 2009, 
Matés et al. 2012). Reactive oxygen and nitrogen species are traditionally viewed as 
harmful. However, controlled production of ROS and antioxidants in normal cells is 
vital for regulating signalling pathways. Reactive oxidants act in concert with the anti-
oxidant defence system to ensure the cells response to oxidants are adequate for the 
organism needs. Apoptosis can be triggered by numerous factors including drugs, 
pathophysiologic conditions, metals, ROS, pro-oxidants, ionising radiation and more 
(Kannan and Jain 2000). Table 1.2 displays a partial list of some of these inducers. 
 
Table 1.2 Inducers of oxidative stress and apoptosis. 
Inducer of oxidative stress and apoptosis* 
Reactive oxygen species Hydroxyl radical, superoxide radical, 
H2O2 
Diseases Cancer, Alzheimer’s, Parkinson’s 
Drugs Staurosporine, taxol, cisplatin 
Ionising radiation Gamma, UV radiation 
Metals Iron, copper, chromium, cobalt, mercury, 
cadmium, nickel 
Pro-oxidants Diamide, etoposide, H2O2, semiquinones 
*list is not inclusive. (Kannan and Jain 2000, Shi et al. 2004, Valko et al. 2005, 
Koppenol and Bounds 2012) 
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 Addition of 1 electron to O2 forms O2
•-, a process mediated by xanthine 
oxidase, nicotine adenine dinucleotide phosphate [NAD(P)H], or mitochondrial 
electron transport system. Mitochondria are the main site for production of O2
•- and 
usually oxygen reduction to water is through the mitochondrial electron transport 
chain. However, 1-3% of these electrons leak from the system and produce 
superoxides, which is converted into H2O2 by superoxide dismutase enzymes (SODs) 
and diffuse easily across the plasma membrane. In a series of reactions, Haber-Weiss 
and Fenton reactions, H2O2 and O2
•- can interact with transition metals like copper and 
iron to form OH radicals via the metal catalysed reaction as shown in the equation 
below (Haber and Weiss 1934, Fenton 1984, Birben et al. 2012). 
 
Metal3+ + O2  Metal2+ + O2 
Metal2+ + H2O2  Metal3+ + OH- + •OH 
 
 OH radicals are the most reactive form of ROS and can lead to DNA, proteins, 
lipids, and carbohydrates damage. Typically, the mechanisms by which ROS induce 
apoptosis involve caspase activation, receptor activation, mitochondrial dysfunction 
and BCL-2 family proteins. Depending on the cellular content, various protein kinase 
activities modulate the apoptotic program such as mitogen-activated protein kinases 
(MAPK), protein kinases –B/ -C (PKB/ PKC) as well as their corresponding 
phosphatases (Ryter et al. 2007).   
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1.2.2 Glutathione 
 
Anti-oxidants function to counterbalance the effects of oxidants. There are enzymatic 
anti-oxidants (catalase, superoxide dismutase, glutathione peroxidase, etc.) and non-
enzymatic anti-oxidants (vitamin A, vitamin C, vitamin E, β-carotene, low molecular 
weight compounds, GSH, etc.) (Birben et al. 2012). Glutathione (GSH) is a vital 
component in the cellular anti-oxidant defence mechanisms that protect cells from 
oxidative stress. The ratio between oxidised and reduced GSH in the body is one of 
the major determinants of oxidative stress. GSH exhibits anti-oxidant effects by 
detoxifying H2O2 and lipid peroxide via glutathione peroxidase (GPx). GSH donates 
its electron to H2O2 and reduce it to H2O and O2. Oxidised glutathione (GSSG) is 
reduced into GSH by the enzyme GSH reductase using NADPH as the electron donor 
(Deponte 2013). GSH also protects cells from apoptosis by interacting with anti-
apoptotic and pro-apoptotic signalling pathways (Masella et al. 2005). When cell 
undergoes oxidative stress, intracellular GSH is expected to deplete. Over formation 
of GSSG may exceed the ability of the cell to recycle it to GSH during oxidative 
stress resulting in a net loss of intracellular GSH (Nur et al. 2011). Consequently, 
depletion of intracellular GSH can cause or result in oxidative stress that leads to cell 
death through ROS or oxidative stress-mediated mechanisms. Cell death that is 
independent of ROS formation has also been reported in GSH depleted cells (Pias and 
Aw 2002, Franco et al. 2007). GSH depletion and the possible mechanisms involved 
in the induction of apoptosis are shown in Figure 1.4.  
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Figure 1.4 Induction of apoptosis and GSH depletion. 
Apart from ROS formation, depletion of GSH is involved in the induction of 
apoptosis by activating executioner caspases and triggering transition of 
mitochondrial permeability. Depletion of GSH triggers pro-apoptotic functions like 
formation of apoptosome and release of cytochrome c (A). Increased GSSG induces 
formation of protein mixed disulfides (PSSG). Increased in PSSG accompanies 
apoptosis, induced by FasL (B). Hence depletion of GSH and increase in GSSG can 
promote formation of PSSG (Circu and Aw 2008, Franco and Cidlowski 2012). 
Figure taken from Franco and Cidlowski (2012). 
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1.3 Semi-synthetic natural products and cancer 
 
It has been reported that in European pharmacies, 50% of the top fifty drugs sold are 
from natural products source and approximately 80% of the world’s population rely 
on natural products as drugs or food/ herbal supplements (Zhu et al. 2004). 
Comparably, an analysis on source of novel drugs from 1981 to 2010 revealed that 
less than 40% of chemical entities were discovered without an inspiration from 
natural product structures (Newman and Cragg 2012). In pharmaceutical research, 
nature provides the main source of compounds. They present an organic chemical 
compound of interest or serves as a source of inspiration in novel drug designs.  
 
 Disease evolution and development of resistance from the human body 
desperately urge the development of new drugs in different areas of research 
including pharmacology, natural product chemistry, molecular biology, synthetic 
organic chemistry, biochemistry and more (Lourenço et al. 2012). The ability to 
complete- or semi-synthesise compounds is important in most cases where the 
availability of natural sources is scarce and there is a need to produce sufficient 
materials for biological screening and application. However, the biochemistry 
involved in the biosynthesis of active molecules is complex and continues to be 
challenging for scientists. The slow progress in treating fatal diseases such as cancer 
indicates a rising need for novel approaches to physiological targets through effective 
therapeutics delivery.  
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 Development of natural product derivatives remains an important goal in 
enhancing the bioactivity of a compound. The different strategies for designing and 
semi-synthesising a natural product analogue include function-oriented synthesis, 
biology-oriented synthesis, hybrid molecules, and complexity to diversity (Maier 
2015). Example of different ways to optimise a compound includes modification of 
the functional groups, inversion or addition of stereocentres (Cragg et al. 2009). The 
privileged structure of natural products is that there are endless ranges of new 
chemical structures yet to be discovered and these ready available structures are a 
large source of biologically active compounds. Introducing natural products 
derivatives to chemical structures, that are often considered extremely unstable, has 
the ability to develop a compound with increased stability. A major drawback of 
using natural products as drug leads is that they exist in very small quantities. For 
example, dolastatin, an inhibitor of the P388 lymphocytic leukaemia growth (Pettit et 
al. 1989), isolated from the Indian Ocean only yielded 4 x10-7% of 6.2 mg from 1,600 
kg of wet sea hare. Hence, the great need to synthesise compounds in the laboratory 
becomes obvious considering the percentage of low yield and the damage made to the 
ecological system. These lead compounds can then be further developed into 
analogues and complexes, which in turn can be pharmacologically optimised via SAR 
studies (Cragg et al. 2009). A good example of the advantages of semi-synthesising is 
the semi-synthesis of Taxol, a naturally occurring compound isolated from Pacific 
yew tree (Wall and Wani 1996) that exhibits anti-cancer and anti-leukaemic 
properties (Wani et al. 1971). Total synthesis of Taxol involves 30 steps whereas the 
semi-synthesis of Taxol using 10-deacetylbaccatin as starting material, found 
abundantly in the needles of many of the Taxus species (Kingston 2008, Cragg et al. 
2009), narrowed down the synthesis of Taxol to only 3 steps.  
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1.4 Cardamonin as potential lead compound 
 
Cardamonin is a naturally occurring chalcone that was first isolated from the seeds 
section of Amomum subulatum from the Zingiberaceae family (Bheemasankara et al. 
1976). Cardamonin was also reported in other species of the Zingiberaceae (Jantan et 
al. 2008, Chow et al. 2012, Zhang et al. 2014), Nepenthaceae (Ahmad et al. 2006) and 
Piperaceae (de Castro et al. 2015) family. Figure 1.5 displays the chemical structure 
of cardamonin, a chalcone belonging to the flavonoid family.  
  A 
 
  B 
 
Figure 1.5 Chemical structures of cardamonin and chalcone. 
1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one, cardamonin (A) and 
1,3-diphenyl-2-propen-1-one, chalcone (B). 
  
 The aromatic enones core structure of chalcone, 1,3-diphenyl-2-propenone is 
often responsible for the yellow pigmentation of plants (Ni et al. 2004, Yadav et al. 
2011, Sahu et al. 2012). In fact, the name chalcone originated from the Greek word 
chalkos meaning copper/ bronze. Flavonoids are subclasses of polyphenols, many of 
which have the ability to alter metabolic processes contributing to positive impact on 
health (Beecher 2003). Flavonoids are aromatic compounds with a phenylchromanone 
unit, which consists of two benzene rings linked by an oxygen atom and 3 carbons to 
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form a central pyrone ring. Previous studies have shown that flavonoids possess 
antimitotic activity (Cárdenas et al. 2006), inhibition properties of cyclin-dependent 
kinases, aromatase, protein kinase C or topoisomerase (Hirvonen et al. 2001) making 
this group of family ideal as an anti-cancer treatment. A plethora of studies have 
shown the anti-cancer potential of both natural and synthetic flavonoids (Ren et al. 
2003, Teillet et al. 2008, Khoo et al. 2010, Shukla and Gupta 2010, Batra and Sharma 
2013). Natural flavonoids appear in diverse forms due to their substitution pattern via 
hydroxylation, methoxylation, glycosylation or prenylation (Menezes et al. 2016). 
Depending on the opening of the central pyran ring or the saturation level of 
flavonoids, they are further categorised into different subclasses including chalcones, 
flavanones, flavonols, flavones and isoflavones (Harborne and Williams 2000). In the 
last decades, several types of chalcones have attracted much attention in medicinal 
chemistry including cardamonin (Win et al. 2007, Ohtsuki et al. 2009, Lin et al. 2012, 
Qin et al. 2012, Yadav et al. 2012), licochalcone A (Xiao et al. 2011), xanthoangelol 
(Tabata et al. 2005), xanthohumol (Gerhauser et al. 2002, Magalhães et al. 2009), and 
hesperidin methyl-chalcone that has reached clinical trials testing stage (Boyle et al. 
2003). Numerous studies have reported the cytotoxicity (Murakami et al. 1993, Li et 
al. 2008, Simirgiotis et al. 2008, Dzoyem et al. 2012, Kuete et al. 2014) and oxidative 
state (Mohamad et al. 2004, Ahmad et al. 2006, Li et al. 2008, Simirgiotis et al. 2008, 
Aderogba et al. 2012, Yadav et al. 2012) of cardamonin. Table 1.3 summarises 
various studies carried out to determine the cytotoxicity and oxidative/ anti-oxidative 
properties of cardamonin. Overall, a large number of studies reported notable 
cytotoxicity properties in cardamonin however; there are conflicting findings on the 
oxidative state of this compound where cardamonin has shown the ability to act as a 
pro-oxidant as well as an anti-oxidant.  
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Table 1.2 Summary of cytotoxicity and oxidative/ anti-oxidative properties of 
cardamonin. 
Cytotoxicity Studies 
Findings Mode of study Reference 
Cardamonin inhibited the growth and proliferation of 
multiple myeloma cells in a dose dependent manner 
against RPMI 8226, U-266, and ARH-77 cell lines 
following 24 hrs and 48 hrs treatment. In RPMI 8226 
cells, Cardamonin activated caspase-3 and PARP; down-
regulated the expression of anti-apoptotic proteins Bcl-2, 
Bcl-xL, survivin, XIAP, cIAP-1 and cIAP-2; down-
regulated expression of IKKα, IKK-β, IκBα; inhibited 
phosphorylation of NF-κB which led to significant 
decrease of intracellular p65 in cell nucleus. 
Human multiple myeloma 
cells (RPMI 8226, U-266, 
ARH-77) 
Qin et al. 
(2012) 
Cardamonin displayed cytotoxicity against K-562 and 
SMMC-7721 cell lines with IC50 values of 3.2 mg/L 
(11.84 µM) and 3.5 mg/L (12.95 µM) respectively. 
Human chronic 
myelogenous leukemia 
(K-562) and human 
hepatoma (SMMC-7721) 
cells 
Tang et al. 
(2010) 
Cardamonin exhibited cytotoxicity against DLD1 cells 
with IC50 values of 41.8 µM following 24 hrs treatment; 
lowered the expression of Bcl-xL protein, enhanced death 
receptor 5 (DR5) and death receptor 4 (DR4) following 
the activation of caspase-3, -8 and -9 in DLD-1/TR cells, 
sensitising TRAIL-resistant cells. 
Human gastric 
adenocarcinoma (AGS) 
and TRAIL-resistant 
human colon cancer 
(DLD-1/TR) cells 
Ohtsuki et al. 
(2009) 
Cardamonin displayed cytotoxicity against A549, L-02, 
SGC-7901, MDA-MB-231, SMMC-7721, H7402, HepG2, 
4T1luc with IC50 values of  
109.79 µg/mL (406.21 µM), 33.16 µg/mL (122.69 µM), 
16.58 µg/mL (61.34 µM), 
12.32 µg/mL (45.58 µM), 
16.74 µg/mL (61.94 µM), 
4.91 µg/mL (18.17 µM), and 
14.34 µg/mL (53.06 µM), respectively following 48 hrs 
treatment; Cardamonin decreased Bcl-2 expression, 
increased Bax protein expression, cleaved caspase-3 and-
9, and induced G2/M-phase arrest in MDA-MB-231 cells. 
Human lung carcinoma 
(A549), normal human 
hepatocyte (L-02), human 
gastric carcinoma (SGC-
7901), human breast 
cancer (MDA-MB-231), 
human hepatocarcinoma 
(SMMC-7721), human 
liver cancer (H7402), and 
human liver carcinoma 
(HepG2) 
Mi et al. 
(2016) 
Cell viability of HCT116, KBM-5, U-266, MIA PaCa-2, 
DU145 and PC-3 cell lines pre-treated with 20 µM 
Cardamonin for 24 hrs were ≃45, 91, 93, 90, 88 and 89% 
respectively. Cardamonin enhanced TRAIL-induced 
apoptosis from 7 to 81% and activates caspase-3, -8, -9 
and cleaved PARP in HCT116 cells. Cardamonin up-
regulated DR5 and DR4 expression in a dose- and time-
dependent manner; down-regulated expression of decoy 
receptor 1 (DcR1) but did not affect decoy receptor 2 
(DcR2), effects were not cell-type specific. Cardamonin 
down-regulated expression of survival proteins (cIAP-1, 
cFLIP, XIAP, Bcl-2 and survivin) and up-regulated 
expression of pro-apoptotic protein (Bax) in HCT116 
cells. 
Human colon 
adenocarcinoma 
(HCT116), human chronic 
leukemic cells (KBM-5), 
human multiple myeloma 
(U-266), human 
pancreatic carcinoma 
(MIA PaCa-2), human 
prostate cancer cells (PC-
3 and DU145) 
Yadav et al. 
(2012) 
Cardamonin displayed cytotoxicity against PC-3 cells with 
50% of growth inhibition (GI50) of 11.35 μg/mL (42 µM) 
following 48 hrs treatment; decreased expression of NF-
κB1 and induced apoptotic cell death as proven by DNA 
degradation Cardamonin-treated PC3 cells. 
Human prostate cancer 
cells (PC-3) 
Pascoal et al. 
(2014) 
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Cardamonin (30 µM) exhibited 63.2% inhibitory effect 
against A549 cells following 48 hrs treatment. 
Cardamonin decreased number of synthesis (S) phase 
cells, inhibited DNA synthesis and increased A549 
apoptotic cells.  
Human lung carcinoma 
(A549) 
Tang et al. 
(2014) 
Cardamonin displayed no effect on cell viability at all 
concentrations tested (≤ 50 µM) following 17-20 hrs 
treatment. 
RAW 264.7 cells Israf et al. 
(2007) 
Cardamonin displayed cytotoxicity against SW480 cells 
with IC50 value of 35 µM following 72 hrs treatment. 
Human colon cancer cells 
(SW480) 
Simirgiotis et 
al. (2008) 
Cardamonin inhibited proliferation of β-catenin response 
transcription (CRT)-positive SW480, DLD-1, HCT116 
and LS174T cells in a dose-dependent manner following 
48 hrs treatment; increased cells in G2/M phases from 
18.55% to 35.42% compared to untreated control 
following 24 hrs treatment with 80 µM cardamonin. 
Human colon cancer cells 
(SW480, DLD-1, 
HCT116, LS174T) 
Park et al. 
(2013) 
Cardamonin did not affect cell viability at all 
concentrations tested (50-0.78 µM) and viability was 
always more than 95% following 17-20 hrs treatment. 
Recombinant mouse 
interferon gamma and E. 
coli LPS (strain 055:B5)-
induced RAW 264.7 cells  
Ahmad et al. 
(2006) 
Cardamonin displayed cytotoxicity against L-02 and 
HepG2 cells with IC50 value of 30.90 µM and 22.63 µM 
respectively following 48 hrs treatment. 
Human normal liver cells 
(L-02) and human 
hepatoma cells (HepG2) 
Li et al. 
(2008) 
Cardamonin displayed cytotoxicity against THP-1, PC-3 
and MCF-7 cells with IC50 value of 32.5 µM, 49 µM and 
44 µM respectively, both A549 and HeLa cells displayed 
IC50 values > 50 µg/ mL (184.99 µM). 
Human lung carcinoma 
(A549), human breast 
carcinoma (MCF-7), 
human prostate cancer 
cells (PC-3), human 
cervical carcinoma 
(HeLa), and human acute 
monocytic leukemic cell 
(THP-1) cell lines 
Dzoyem et al. 
(2012) 
Cardamonin inhibited cell viability against SKOV3 cells 
in a dose-dependent manner from the concentrations tested 
(1, 3, 10 and 30 µM) following 48 hrs treatment. 
Human epithelial ovarian 
cancer (SKOV3) cell line  
Xue et al. 
(2016) 
Cardamonin inhibited cell viability CD133+ GSC in a 
dose-dependent manner from the concentrations tested 
(20, 30 and 40 µM) following 72 hrs treatment. 
Human glioblastoma stem 
cells (CD133+ GSC) 
Wu et al. 
(2015) 
Oxidative/ Anti-oxidative Studies 
Cardamonin inhibited the generation of intracellular ROS. Intracellular ROS level of 
recombinant mouse 
interferon gamma and E. 
coli LPS (strain 055:B5)-
induced RAW 264.7 cells  
Ahmad et al. 
(2006) 
Cardamonin generated ROS in a dose-dependent manner; 
pre-treatment with NAC reduced DR5 and DR4 
expression; NAC reversed effect of TRAIL-induced 
cardamonin cleavage of caspase-3, -8 and PARP in 
HCT116 cells. 
Intracellular ROS level of 
HCT116 cells 
Yadav et al. 
(2012) 
DPPH: Cardamonin displayed anti-radical DPPH activity 
with IC50 value of 124 µM; FRAP: Cardamonin displayed 
ferric reducing anti-oxidant power of 173 µM (expressed 
as Trolox equivalents/ 500 µmol). 
Anti-radical DPPH 
activity, FRAP 
Simirgiotis et 
al. (2008) 
DPPH and superoxide anion assay: effects of Cardamonin 
were negligible at tested concentrations (≤ 200 µM). 
DPPH, superoxide anion  Li et al. 
(2008) 
Cardamonin and pinocembrin did not inhibit 50% of 
DPPH free radical at 200 μM, the highest concentration 
tested. 
DPPH activity Aderogba et 
al. (2012) 
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Recently, cardamonin has also attracted researchers to produce semi-synthetic 
derivatives/ analogues using cardamonin as the lead compound. A recent study 
investigated the cytotoxicity properties of two cardamonin analogues, 4,4’-
dihydroxylchalcone (DHC) and 4,4’-dihydroxy-2’-methoxychalcone (DHMC), on 
lung cancer cells and results revealed that these analogues inhibited the survival of 
both primary lung cancer cells and lung cancer cell lines by suppressing the activation 
of NF-kappaB pathway (He et al. 2014). Furthermore, these two analogues were 
reported to show low cytotoxicity against normal lung cell lines, highlighting the 
cytotoxic selectivity of these analogues. Other studies carried out on compounds 
structurally related to cardamonin have demonstrated inhibitory effects on prostate 
cancer cells (Sun et al. 2010) as well as lung cancer cells (Nam et al. 2003, Srinivasan 
et al. 2009).  
 
 In this study, cardamonin derivatives semi-synthesised via metal 
complexation, cyclisation and condensation reactions (Break et al. 2018) were used to 
identify the bioactivity of novel bioactive analogues. Table 1.4 displays the chemical 
structures of the cardamonin analogues used in this study.  
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Table 1.4 Chemical structures of the cardamonin analogues used in this study. 
Compounds Chemical Structures 
Acetyl-cardamonin 
 
 
 
Allyl-cardamonin 
 
 
 
OBn-cardamonin 
 
OMe-cardamonin 
 
Cardamonin-Cu(II) 
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Cardamonin-Fe(II) 
 
Cardamonin-B 
 
Benzoyl-cardamonin 
 
 
Phenylamine-
cardamonin 
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Methoxyamine-
Cardamonin 
 
 
Hydroxylamine-
Cardamonin 
 
 
Urea-cardamonin 
 
 
Thiourea-cardamonin 
 
 
4-fluoro-cardamonin 
 
Tetrahydro-
cardamonin 
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Flavanol-cardamonin 
 
 
Flavanone-
Cardamonin 
 
 
Cardamonin-I(II) 
 
 
Cardamonin-Br(II) 
 
Hydrazinium-
cardamonin 
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1.5 Adherent and suspension culture 
 
To date, the most common and simplest way to measure susceptibility of cells to any 
treatment is the cytotoxicity test (Kepp et al. 2011, Riss et al. 2013). Understanding 
the susceptibility difference between adherent and suspension cell culture is crucial 
for drug discovery and development. In general, suspension type cells lack the 
expression of adhesion molecules. Thus, suspension cells are non-adhesive and are 
suspended in the growth medium. Examples of suspension cells are monocytes and T-
lymphocytes derived from myeloid and lymphoid hematopoietic stem cells, which can 
be isolated from leukaemic patients (Sloma et al. 2010, Buss and Ho 2011, Jan et al. 
2011). In contrast, adherent cells derive from solid tissues with surface integrin 
expressions and focal adhesion molecules (Gumbiner 1996, Giancotti and Ruoslahti 
1999, Hood and Cheresh 2002, Meyer et al. 2004). Examples of adherent cells are 
mature macrophages, breast cancer, lung cancer, liver cancer and other solid tumours.  
 
1.5.1 THP-1 cell line and differentiation into mature macrophages 
 
THP-1 cell line is a human monocytic cell first established from an individual with 
acute monocytic leukaemia. These cells have the ability to produce esterase and 
lysosomes and were characterised as phagocytes. The Fc receptor and complement 
receptor 1 on THP-1 recognises antibodies and complement component 3 on 
pathogens or infected cells, triggering phagocytosis (Tsuchiya et al. 1980). 
Subsequently, researchers found that introduction of THP-1 to phorbol-12-myristate-
13-acetate (PMA) changed the cells from suspension to adherent phase (Tsuchiya et 
al. 1982) and PMA was determined as the most effective differentiation agent for 
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obtaining mature THP-1-derived macrophages (Chanput et al. 2014). These 
differentiated THP-1 cells exhibit striking similarities to macrophages 
morphologically. Since then, many studies have been carried out using THP-1-
derived macrophages as a representative macrophage cell line and an investigative 
model in in vitro studies (Auwerx 1991, Schroecksnadel et al. 2011). Another type of 
stimuli often used to induce macrophage differentiation in monocytes is 1,25-
dihydroxyvitamin D3 (VD3) (Daigneault et al. 2010). Further studies have shown that 
before PMA initiates cell differentiation, treatment with these stimuli must first 
induce an inhibition of cell growth (Traore et al. 2005). PMA has been shown to 
initiate cellular generation of ROS, modulate expression of some cell cycle regulators 
and inhibit the cell cycle of THP-1 cells at G1-phase. PMA-induced differentiation in 
THP-1 cells also up-regulates p21 at protein and mRNA level through a protein 
kinase C (PKC)-mediated signaling mechanism that involves mitogen-activated 
protein (MAP) kinase activation (Traore et al. 2005).  
 
1.5.2 Mitogen-activated protein kinase 
 
There are four subgroups of the MAP kinase including extracellular signal-regulated 
kinases (ERKs), stress-activated protein kinase or c-jun N-terminal kinase (SAPK/ 
JNK), big MAP kinase 1 (BMK1) and p38 group (Zarubin and Han 2005). p38 MAP 
kinase plays a pivotal role in several biological processes and signal transduction. To 
date, there are four identified p38 family variants: p38α, p38β (Jiang et al. 1996), 
p38γ (Li et al. 1996) and p38δ (Jiang et al. 1997). Of these four p38 groups, p38γ are 
expressed differentially depending on type of cells whereas p38α and p38β are 
expressed ubiquitously. Other study reports the activation of MAP kinase signaling 
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cascade is downstream of PKC activation, an early event in the differentiation process 
inducing cell cycle arrest (Sugibayashi et al. 2001). The team reported that PKC 
inhibitor and MAP kinase inhibitor could inhibit the differentiation and growth arrest 
of human prostate cancer cell line, TSU-Pr1. Furthermore, MAP kinase species such 
as p38 have been shown to be strongly activated by ROS or intracellular redox state 
oxidative shift (Soh et al. 2003). PMA-stimulated THP-1 monocytes that promote 
myeloid cells maturation to mature macrophages also leads to surface expression of 
differential cell markers. Figure 1.6 depicts the differential antibody markers of THP-
1 monocytes and THP-1-derived macrophages after 72 hrs 100 nmol/L PMA 
treatment followed by 24 hrs PMA-free medium using flow cytometry (Mittar et al. 
2011). 
 
 Among these markers, CD11b integrins are significantly expressed on the cell 
surface of THP-1-derived macrophages and commonly used as a macrophage marker 
(Gonzalez-Juarrero et al. 2003, Murray and Wynn 2011). It is well established that 
cell matrix adhesion via integrins allow cell survival and protects cells from 
undergoing apoptosis (Frisch and Ruoslahti 1997).  
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Figure 1.6 THP-1 monocytes and THP-1-derived macrophages cell surface 
markers.  
Comparison of antibody markers in THP-1 monocytes and THP-1-derived 
macrophages using flow cytometry and expressed as percentage of positive cells in a 
heat map. Figure taken from Mittar et al. (2011). 
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1.6 Aims  
 
Previous studies have shown that cardamonin exhibit cytotoxic and oxidative/ anti-
oxidative properties in different cell lines. Efforts were made to enhance the 
bioactivity of cardamonin by producing semi-synthetic derivatives using cardamonin 
as the lead compound. The objectives of this study are to screen these novel 
cardamonin derivatives and to determine compounds that are more cytotoxic than 
cardamonin and to further investigate the structure activity relationship of these 
compounds. Furthermore, the identified active compounds will be tested for 
cytotoxicity against a range of normal and carcinoma cell lines to establish the 
toxicity of the compounds. As previous studies have reported that suspension cells are 
more susceptible to inhibition of cell growth compared to adherent cells, this study 
intends to examine the differential susceptibility between both cell state by looking at 
their response towards cardamonin and its active derivatives/ complexes. Overall, the 
cell line that is most susceptible to these compounds will be further used to 
investigate the mode of cell death looking into the effects on morphological changes, 
PS externalisation, caspase activation and MMP alteration. Finally, as cardamonin has 
been reported to possess both oxidative and anti-oxidative properties, this study aims 
to elucidate the oxidative effects in the cells in the presence of cardamonin and its 
derivatives/ complexes. The change in oxidative state will be determined by 
quantifying the intracellular levels of ROS and GSH. The effects on cell viability will 
also be determined in the presence or absence of various anti-oxidants. Generally, this 
study will provide a better understanding of cardamonin as a lead compound and its 
active derivatives/ complexes may offer a number of targets for therapeutic 
intervention particularly in cancer research.  
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Reagents 
Materials Source 
2x Laemmli Sample Buffer (1610737) Bio-Rad, USA 
3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium (G1111) 
Promega, USA 
40% acrylamide solution Sigma, USA 
Absolute ethanol (E0105/3000) J Kollin Chemical, UK 
Ammonium persulfate (A9164) Sigma, USA 
Annexin V-FITC binding buffer (556454) BD Pharmingen, USA 
Annexin V-fluorescence isothiocyanate 
(556420) 
BD Pharmingen, USA 
Anti- human FITC-CD11b Biolegend, USA 
Anti-caspase-3 (SC-7148) Santa Cruz Biotechnology, USA 
Anti-caspase-8 (D35G2) Cell signalling Techonology, 
USA 
Anti-caspase-9 (9508) Cell signalling Techonology, 
USA 
Anti-PARP (ALX-804-210-R050) Alexis Biochemicals, 
Switzerland 
Anti-β-actin (A5441) Sigma, USA 
Benzyloxycarbonyl-phenylalanine-alanine- 
chloromethylketone, Z-FA-CMK (03CK009) 
MP Biomedicals, USA 
Benzyloxycarbonyl-valine-alanine-aspartic acid- 
fluoromethylketone, Z-VAD-FMK (N-1560) 
Bachem, Switzerland 
Bovine serum albumin (A2058) Sigma, USA 
D-cysteine Sigma, USA 
Dihyrdoethidine (D-23107) Molecular Probes, USA 
Dimethyl sulfoxide (D2650) Sigma, USA 
Dithiothreitol (D9779) Sigma, USA 
Enhanced chemiluminescence reagent 
(RPN2106) 
GE Healthcare, UK 
Ethylene-diamineteraacetic acid (E5134) Sigma, USA 
Fetal bovine serum Gibco, USA 
Glutathione Sigma, USA 
Glycerol (G5516) Sigma, USA 
Glycine (G7126) Sigma, USA 
Goat anti-mouse IgG horseradish peroxidase 
(P0447) 
Dako, Denmark 
Goat anti-rabbit IgG HRP(P0448) Dako, Denmark 
Hoechst 33358 (H1398) Molecular Probes, USA 
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Hybond C membrane (RPN2020D) GE Healthcare, UK 
L-cysteine Sigma, USA 
Lymphoprep Axis Shield, Norway 
Methanol (106009) Merck, USA 
Monochlorobimane (69899) Sigma, USA 
Mouse FITC-IgG1 negative control Dako, Germany 
N-acetyl cysteine (A9165) Sigma, USA 
p38 MAP Kinase Inhibitor IV (SML0543) Sigma, USA 
Paraformaldehyde (P6148) Sigma, USA 
Penicillin-streptomycin antibiotic Sigma, USA 
Phenazine methosulfate (P9625) Sigma, USA 
Phenylmethylsulfonyl fluoride (P7626) Sigma, USA 
Phorbol 12-myristate 13-acetate (P8139) Sigma, USA 
Phosphate buffered saline Sigma, USA 
Ponceau S (P3504) Sigma, USA 
Propidium iodide (P4170) Sigma, USA 
Quick Start Bradford (500-0205) Bio-Rad, USA 
Rabbit anti-goat IgG HRP (P0160) Dako, Denmark 
RPMI-1640 with L-glutamine (11875-093) Gibco, USA 
SB202190 (S7067) Sigma, USA 
Skim milk Sunlac, Malaysia 
Sodium chloride (6533-00) R&M, UK 
Sodium Dodecyl Sulfate (161-0418) Bio-Rad, USA 
Staurosporine (S4400) Sigma, USA 
SuperSignal molecular weight protein ladder Thermo Scientific 
Tetramethyl rhodamine ethyl ester (T-669) Molecular Probes, USA 
Tetramethylethylenediamine (T9281) Sigma, USA 
Tris base (T1503) Sigma, USA 
Triton X-100 (T8787) Sigma, USA 
Trolox Sigma, USA 
Tryphan blue (T8154) Sigma, USA 
Trypsin EDTA Gibco, USA 
Tween-20 (P5927) Sigma, USA 
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2.1.2 Cell lines 
 
THP-1 human acute monocytic leukaemic, A549 human lung adenocarcinoma, 
MRC5 human lung normal, Hs68 human normal foreskin and Jurkat T human acute 
lymphoblastic leukaemia cell lines used in this study were obtained from American 
Type Culture Collection (ATCC). HK1 human nasopharyngeal carcinoma cell line 
was generously provided by the University of Hong Kong through local collaboration 
with the Institute of Medical Research Malaysia. 
  
2.1.3 Compounds 
 
The following compounds were semi-synthesised and provided by Mohammed 
Khaled Break from the Centre for Natural and Medicinal Product Research at the 
University of Nottingham Malaysia Campus: cardamonin, acetyl-cardamonin, allyl-
cardamonin, OBn-cardamonin, OMe-cardamonin, cardamonin-Cu(II), cardamonin-
Fe(II), cardamonin-B, benzoyl-cardamonin, phenylamine-cardamonin, 
methoxyamine-cardamonin, hydroxylamine-cardamonin, urea-cardamonin, thiourea-
cardamonin, 4-fluoro-cardamonin, tetrahydro-cardamonin, flavanol-cardamonin, 
flavanone-cardamonin, cardamonin-I(II), cardamonin-Br(II), and hydrazinium-
cardamonin. The structures of these novel compounds were established using infrared 
spectroscopy, 1H NMR, 13C NMR and mass spectrometry techniques (Break et al. 
2018). 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Maintaining Adherent Cells 
 
Adherent cells including human lung cancer A549, human nasopharyngeal cancer 
HK1, human normal lung MRC5, human normal foreskin Hs68, THP-1-derived 
macrophages were maintained as monolayer in T25 or T75 flasks of 10 mL or 20 mL 
RPMI-1640 growth medium with L-glutamine supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 5% penicillin/ streptomycin (pen/ strep) 
(RPMI10) respectively at 37°C in a humidified atmosphere and 5% CO2. All cells 
except THP-1-derived macrophages were split and passaged by trypsinisation to a 
fresh culture vessel when growth reached 70-80% confluency. Old medium in the 
flask was discarded and cells were washed twice with phosphate buffered saline 
(PBS) then added with 1X trypsin and incubated for 5 mins at 37 °C. To dislodge 
cells, cells were passaged mechanically by tapping the flask gently. Equal parts of 
RPMI-1640 complete medium were added to trypsinised cells in order to neutralise 
trypsin. Cells were collected and centrifuged at 1,800 revolutions per minute (rpm) 
for 5 mins and the pellet was re-suspended in 1 mL RPMI10 where cell number was 
determined. 
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2.2.1.2 Maintaining Suspension Cells 
 
The human acute lymphoblastic leukemic cell line, Jurkat T cells, used in this study 
was clone E6-1 established from a 14 year old male’s peripheral blood suffering from 
acute lymphoblastic leukaemia (Schneider et al. 1977). The human acute monocytic 
leukemic cell, THP-1, was derived from a one year old male’s peripheral blood. Both 
Jurkat T cells and THP-1 monocytes were cultured in RPMI10 and kept in a 37 ºC 
incubator with humidified atmosphere and 5% CO2. Cells were seeded at a density 
between 3 x 106 cells/mL to 5 x 106 cells/mL and subcultured every 2-3 days. For 
experimental studies, suspension cells were collected and centrifuged at 1,000 rpm for 
5 minutes and the pellet was re-suspended in 1 mL RPMI10 where cell number was 
determined. 
 
2.2.1.2.1 Isolation of Mononuclear Cells 
 
Lymphoprep™ is a density gradient medium used to isolate live from dead 
mononuclear cells. 20 mL of Jurkat T cells growing in RPMI10 were collected from 
T75 flask and carefully layered onto 20 mL of Lymphoprep™ in a tilted 50 mL tube 
and centrifuged at 1,800 rpm for 20 mins at 25 °C (without break). The Jurkat 
mononuclear cells that retained at the medium/ Lymphoprep™ interface were gently 
removed. Collected Jurkat T cells were washed with PBS twice at 1,000 rpm for 10 
mins at 25 °C and re-suspended in RPMI10, kept at 37 ºC incubator with humidified 
atmosphere and 5% CO2 until needed. Layered Jurkat T cells’ viability was routinely 
found to be higher than 90%.  
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2.2.1.3 Cell Counting  
 
Cell pellet re-suspended in 1 mL RPMI10 medium was carefully and gently pipetted to 
break the cell pellet. 20 µL of cell suspension and 180 µL of Tryphan blue solution 
were transferred to a centrifuge tube giving a 10x dilution of the cell suspension. The 
suspension was gently mixed and 10 µL of the solution was carefully placed into each 
side of the haemocytometer with coverslip. A handheld counter was used to count 
cells in each of the four corners and centre squared of the haemocytometer. Total 
number of viable cells, unstained by Tryphan blue, was counted. The calculation for 
number of cells per mL is described below: 
 
• Cells/mL = average count per square x dilution factor x 
104 (volume correction factor for the haemocytometer 
where each square is 1 x 1 mm and the depth is 0.1 mm) 
• Total cells = cells/mL x total original volume of cell 
suspension from which the sample was taken 
 
2.2.1.4 Cryopreservation  
 
Cryopreservation technique is used to conserve cells in earlier passage in order to 
maintain the consistency of cell characteristic throughout the experiment. Retrieval of 
cryopreserved cells is needed when cells reached a higher passage number or in the 
case of contamination of cultures. Confluent cells were brought into suspension form 
and centrifuged to obtain the cell pellet. The supernatant was discarded and pellet was 
gently pipetted in 0.9 mL chilled FBS and the suspension was transferred into a 
cryovial where 0.1 mL of dimethyl sulfoxide (DMSO) was slowly added to the FBS 
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giving a 9:1 ratio of FBS to DMSO. The cryovial was then placed into a pre-chilled 
passive freezer “Mr Frosty” and stored in -20 °C freezer for 1 hr prior to storing in -
80 °C freezer overnight. For long-term storage, cryovial was removed from “Mr 
Frosty” and transferred to the vapour phase of liquid nitrogen storage vessel the next 
day. To retrieve cells from frozen storage, RPMI10 medium was firstly pre-warmed to 
37 ºC and cryovial containing cell culture was retrieved from the frozen storage and 
warmed in 37 ºC water bath until semi-thawed. 1 mL of the pre-warmed RPMI10 
medium was added to the cell suspension and gently pipetted then transferred to a 
T75 flask and topped with 20 mL of the pre-warmed RPMI10 medium. Cells were 
incubated overnight in humidified atmosphere at 37 ºC with 5% CO2. The next day, 
RPMI10 medium containing traces of DMSO was discarded and replaced with fresh 
DMSO-free RPMI10 medium. Cell cultures were maintained for at least one week 
before being used for experimental studies. 
 
2.2.1.5 THP-1 cells 
2.2.1.5.1 Differentiation of THP-1 Monocytes to Macrophages 
 
THP-1 cells growing in suspension were pellet down at 1,000 rpm for 10 mins. THP-
1 monocytes of 5 x 106 cells in 20 mL RPMI10 were used for differentiation in T75 
flask. THP-1 monocytes were induced to differentiate into macrophages with phorbol-
12 myristate 12-acetate (PMA) at a final concentration of 20 ng/mL in RPMI10. Cells 
were incubated for 72 hrs. Differentiated cells were then replaced with fresh PMA-
free RPMI10 medium for 48 hrs (resting phase) before being used for experimental 
studies. THP-1-derived macrophages were displaced as described in Section 2.2.1.1 
followed by cell number determination in Section 2.2.1.3. 
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2.2.1.5.2 Expression of CD11b surface marker in THP-1-derived macrophages 
 
CD11b surface receptors, an α-subunit of β2 integrin, is known to increase 
significantly on surface of mature THP-1-derived macrophages (Figure 1.6). 
Following 72 hrs PMA-induced differentiation and 48 hrs in resting phase, mature 
THP-1-derived macrophages were analysed for the expression of CD11b surface 
antigen. Cells were washed and trypsinised as described in Section 2.2.1.1 and 
brought into suspension form. Once the cell number was determined, 5 x 105 cells 
were aliquot into centrifuge tubes and centrifuged at 1,000 rpm for 10 mins followed 
by washing twice in cold 1X PBS at 1,000 rpm, 4ºC for 10 mins. For unstained 
samples, cells were re-suspended in 300 µL staining buffer (1% BSA in PBS); for 
stained samples, cells were re-suspended in 50 µL staining buffer and 2 µL FITC anti-
human CD11b; whereas for isotype sample, cells were re-suspended in 50 µL staining 
buffer and 2 µL FITC mouse IgG1 negative control. All samples were kept on ice for 
1 hr protected from light. Following incubation, samples were washed twice with 1X 
PBS before being re-suspended in 500 µL staining buffer and analysed with BD 
FACS Calibur flow cytometer. 
 
2.2.2 MTS Cell Viability Assay  
 
The cell viability was evaluated using the Cell Titer 96TM Aqueous Cell Proliferation 
Assay (MTS) containing the reactive compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, and an electron-coupling 
reagent, phenazine methosulfate, (PMS). This assay is based on the reduction of MTS 
tetrazolium into water-soluble purple formazan dye by the mitochondrial succinate 
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dehydrogenase enzymes available in metabolically active cells. The amount of purple 
formazan dye directly correlates to the number of metabolically active cells and can 
be measured at 490 nm wavelength (Cory et al. 1991). 
 
For adherent cells, cells were firstly plated out in RPMI10 in 96-well flat-bottomed 
plates and incubated for 24 hrs to allow for cell attachment and recovery. RPMI10 was 
then carefully removed and replaced with the appropriate treatments in RPMI1 and 
incubated for 24, 48 and 72 hrs. For suspension cells, cells were plated with the 
appropriate treatments in RPMI1 and incubated for 24 hrs. Following treatment and 
incubation, freshly prepared MTS/PMS solution (5 parts of 2 mg/mL MTS and 1 part 
of 0.92 mg/mL PMS) was added to each well and incubated at 37 ºC in the dark for an 
hour. The number of cells seeded and volume of MTS/PMS solution added in the 96-
well plates for the different cell lines are as described in Table 2.1. Prior to measuring 
the absorbance at 490 nm, plates were agitated gently to fully dissolve the formazan 
product. The absorbance was read using a Tecan Infinite 200 microplate reader. 
Absorbance of each sample was subtracted from the blank absorbance value, 
containing media alone and cell viability was expressed as percentage activity 
corresponding to the control. All samples were performed in triplicates for three 
independent experiments. 
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Table 2.1 Number of cells seeded and volume of MTS/ PMS solution added for 
the different cell lines. 
Cell lines Number of cells/ well 
in 96-Well Plates 
MTS/PMS 
solution (µL) 
A549 10,000 10 
HK1 10,000 10 
MRC5 10,000 10 
Hs68 10,000 10 
THP-1 monocytes 50,000 20 
THP-1-derived macrophages 50,000 20 
Jurkat T cells 50,000 20 
 
2.2.3 Nuclear Morphology for Detection of Apoptosis 
 
The morphological changes in Jurkat T cells were determined using a nuclear stain 
Hoechst 33358 and examined using UV microscopy. This DNA-binding dye emits 
blue fluorescence following UV excitation (Latt and Stetten 1976). In brief, cells (5 x 
105 cells/ well) were treated with the IC50 concentrations and incubated for 24 hrs. 
After treatment, cells were collected and washed with chilled PBS (centrifuge at 
3,000 rpm for 15 mins) prior to fixing with 4% paraformaldehyde for 30 mins at room 
temperature. Fixed cells were then counter-stained with 8 µg/mL Hoechst 33358 for 
30 mins at room temperature protected from light. The stained cells were centrifuged 
at 3,000 rpm for 10 mins and pellet was re-suspended in 10 µL glycerol/ PBS (50:50, 
v/v). 5 µL was aliquot from the cell suspension and mounted onto glass slide and 
viewed for morphological changes using an Olympus fluorescence microscope 
(Model BX51). For storage and later viewing, slides were sealed with nail varnish 
around the edge of the cover slips and kept in the dark at 4 ºC. Cells were deemed to 
be apoptotic based upon the characteristic of highly condensed chromatin and/ or 
45 
 
presence of fragmented DNA into apoptotic bodies. In contrast to normal cells, 
condensed chromatic may cause the cell nuclei to appear smaller, crescent-shaped or 
spherical beads around the nucleus of the cell.  
 
2.2.4 Annexin V-FITC Analysis 
 
The externalisation of PS from the inner part to the outer side of the cell bilayer 
member is one of the hallmarks of apoptotic cell death. Annexin-V is a calcium 
dependent protein that binds to PS with higher affinity. Hence, Annexin-V conjugated 
with FITC was used to probe externalised PS on the outer cell membrane enabling 
identification and quantification of apoptotic cells by flow cytometry (Van Engeland 
et al. 1998). A second dye, propidium iodide (PI) was used as a counter stain to 
discriminate between viable cells, early apoptotic and late apoptotic or necrotic cells. 
Cells without Annexin V-FITC and PI stained (AV-PI-) are considered viable cells 
with non-exposed PS and intact cell membrane that excludes both Annexin-V and PI 
stains respectively. AV+PI- stained cells are deemed early apoptotic cells with 
externalised PS but with an intact cell membrane, hence taking up the Annexin-V but 
not PI stain. Cells stained positively with both Annexin-V and PI stains (AV+PI+) are 
regarded as late apoptotic or necrotic cells as PS is translocated to the outer leaflet of 
the plasma membrane and there is loss of cell membrane integrity. In this study, the 
binding of Annexin-V to externalised PS and PI to DNA of membrane-ruptured cells 
on apoptotic cells was measured by flow cytometry (BD FACSVerseTM). Following 
24 hrs treatment with the IC50 concentrations, Jurkat T cells (1 x 10
6) were washed 
twice with chilled PBS and suspended in 1 mL 1 mM CaCl2 (1X Binding Buffer). 100 
µL of the solution was transferred to a 5 mL culture tube and incubated with 2 µL 
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each of Annexin V-FITC and PI in the dark for 30 mins. After incubation, 400 µL of 
1X Binding Buffer was added to the cells and analysed using flow cytometry within 1 
hr. Excitation wavelengths of 488 nm (Annexin V-FITV) and 595 nm (PI) were used. 
Fluorescence data was acquired for 10,000 cells. Staurosporine (STS) was used as 
positive control in this study following 4 hrs treatment of Jurkat T cells with 1 µM 
STS. 
 
2.2.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot 
analysis 
 
Western blotting technique was used to separate and identify the presence of specific 
proteins from a complex mixture of proteins of the cell lysates. The protein fractions 
were separated based on molecular weight through sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS- PAGE). Prior to separation, the proteins 
were denatured and conferred to negative charge in the presence of reducing agent 
dithiothreitol (DTT), SDS and heat. Proteins separated after SDS-PAGE were 
transferred to a membrane and then incubated with proper primary and secondary 
antibodies specific to the protein of interest for visualisation.  
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2.2.5.1 Buffers, resolving gel and stacking gel recipes 
 
Table 2.2 Recipes for buffers and gels. 
Buffers Recipe 
10X TBS (pH 7.6) 24.2g trizmabase, 80g NaCl, top up to 
700 mL with deH2O (adjust pH to 7.6) 
1X TBS 100 mL 10X TBS + 900 mL deH2O 
1X TBS-T (0.1% Tween-20) 100 mL 10X TBS + 900 mL deH2O, 
remove 1 mL and add 1 mL Tween-20 
RIPA lysis buffer 1mL 1M NaCl, 20 µL 0.5M EDTA, 
100 µL 1M Tris–HCl at pH 7.6, 100 µL 
triton-X, 8.73 mL deH2O and 50 µL 
0.2M PMSF (add fresh) 
2X Laemmli loading buffer 20 µL 1M DTT, 500 µL 2X Laemmli 
loading buffer sample buffer (to mix 
with sample 1:1 ratio) 
5X electrode buffer (1L) 15.5g trizmabase, 72g glycine, 25 mL 
20% SDS, top up with 1000 mL deH2O 
1X electrode buffer 200 mL 5X electrode buffer + 800 mL 
deH2O 
Transfer buffer 14.4g glycine, 3.03g trizmabase, 800 
mL deH2O and 200 mL methanol 
12% Resolving gel buffer (16 mL) 6.9 mL deH2O, 4.8 mL 40% 
acrylamide, 4 mL 1.5M Tris-HCl pH 
8.8, 80 µL 20% SDS, 160 µL 10% 
APS, 16 µL TEMED 
4% Stacking gel buffer (5 mL) 3.1 mL deH2O, 0.5 mL 40% 
acrylamide, 1.25 mL 0.5M Tris-HCl pH 
8.8, 25 µL 20% SDS, 50 µL 10% APS, 
5 µL TEMED 
Membrane stripping solution (10 mL) 1.25 mL 0.5M Tris-HCl, 1 mL 20% 
SDS, 1 mL 1M DTT, 6.75 mL deH2O 
(adjust pH to 2.2) 
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2.2.5.2 Preparation of Stacking and Resolving Gels 
 
The gels were cast using Bio-Rad Mini-PROTEAN apparatus. All large (tall plate 
with 1.5 mm spacer) and small glass plates were washed with deH2O and dried 
thoroughly then arranged and locked together securely by a casting frame. A sponge 
was placed between the casting frame containing the glass plates and the casting stand 
to prevent leakage. The casting chamber was checked for leakage by adding 2 mL of 
deH2O. Once no leakage is detected, the deH2O was poured off and any traces of 
deH2O were removed with filter paper. Resolving gel prepared according to Table 
2.2, was carefully pipetted into the space between the large and small glass plates up 
to a level of 2 cm from the top of the short plate. Immediately after pipetting the 
resolving gel, approximately 2 mL of deH2O was gently added onto the resolving gel 
to obtain an even top layer. The resolving gel was then left to polymerise for 1 hr 
before pouring off and removing all traces of deH2O with filter paper. Polymerisation 
is initiated by ammonium persulfate (APS) and catalysed by TEMED (Shi and 
Jackowski 1998). Subsequently, the stacking gel prepared according to Table 2.2 was 
carefully cast on top of the resolving gel and a 10-well comb with 1.5 mm thickness 
was inserted into the space between the plates and left to polymerise for an hour. 
After the stacking gel had polymerised, the plates containing the polymerised gels 
were removed from the casting stand and casting frame and placed in the electrode 
assembly and inside the tank with the short plate facing inwards. The tank was then 
filled up with electrode buffer above the level covering the short plates. The comb 
was then gently removed and the wells were carefully rinsed with electrode buffer. 
The wells were then loaded with the protein fractions.  
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2.2.5.3 Preparation of Cell Lysates 
 
Following 24 hrs treatment with cardamonin, cardamonin-Cu(II) and cardamonin-
Fe(II) using the IC50 values and 4 hrs treatment with 1 µM STS (positive control), 
Jurkat T cells (2 x 106 cells/ mL) were collected and centrifuged at 1,500 rpm for 15 
mins at 4 °C. Cell pellets were washed with chilled PBS twice before being re-
suspended in 50 µL radio-immunoprecipitation assay (RIPA) cell lysis buffer. Freeze-
thaw cycle was carried out three times using liquid nitrogen and 37 °C water bath to 
obtain the cell lysates. The cell lysates were kept at -20 °C freezer until use. 
 
2.2.5.4 Protein Estimation using Bradford Protein Assay 
 
The extracted protein fractions of cell lysates were corrected for amount of protein 
present using the Bradford protein assay. Bovine serum albumin (BSA) was prepared 
as a standard to construct the standard curve at different concentrations of 0, 62.5, 
125, 250, 500, 750, 1000 and 1500 µg/mL as described in Table 2.3. The cell lysate 
samples including the BSA standards were diluted 1:20 with deH2O and 5 µL were 
transferred to 96-well plate containing 250 µL of Bradford reagent. The plate was 
incubated at room temperature protected from light for 30 mins. The absorbance was 
read at 595 nm using a Tecan Infinite 200 microplate reader. A standard curve was 
constructed from the BSA protein standards and the protein concentration of the cell 
lysates were calculated. All samples were performed in triplicates for three 
independent experiments.  
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Table 2.3 BSA standards preparation. 
Tubes Volume of 
Diluent 
(µL) 
Volume of Protein Standard 
(µL) 
Final BSA 
Concentration 
(µg/mL) 
A 10 30 from 2 mg/mL BSA Stock 1500 
B 20 20 from 2 mg/mL BSA Stock 1000 
C 20 20 from Tube A 750 
D 20 20 from Tube B 500 
E 20 20 from Tube D 250 
F 20 20 from Tube E 125 
G 20 20 from Tube F 62.5 
H 20 deH2O only 0 
 
2.2.5.5 Sample Preparation for SDS-PAGE 
 
Cell lysates containing 30 µg of protein were transferred to micro-centrifuge tubes 
and added with equal volume of lysis buffer. Samples were vortexed before and after 
10 mins of boiling at 96 ºC. Protein samples were placed on ice until further use once 
cooled down. Protein samples and 1 µL of protein ladder (Thermo Fisher) were 
carefully loaded into the SDS-PAGE gel wells and the gel was left to run at 120 V 
until the dye reaches the bottom of the resolving gel, approximately 90 mins. 
Following protein separation, the gels were removed from the glass plates and the 
stacking gel was cut away. The resolving gel was left to soak in pre-chilled transfer 
buffer for at least 15 mins prior to western blotting. 
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2.2.5.6 Western Blotting 
 
The separated protein on the SDS-PAGE gel was transferred onto Hybond C 
membrane (Amersham, UK) using the Mini Trans-Blot® Electrophoretic Transfer 
Cell (Bio-Rad). Initially, a piece of Hybond C membrane was cut to size 7 x 10 cm 
along with two pieces of filter paper. The membrane was saturated with deH2O and 
then soaked in pre-chilled transfer buffer with the filter papers and fiber pads for 30 
mins at 4 °C. The transfer sandwich was assembled on the transfer cassette as shown 
in Figure 2.1. The transfer cassette was then placed inside an electrode module and 
transferred into a mini tank filled with transfer buffer and the proteins were 
transferred at 100 V for 1 hr. Once the transfer is completed, the membrane was 
carefully removed and stained with Ponceau-S solution for approximately 1 min to 
confirm the transfer of protein onto the membrane has been successful. The Ponceau-
S solution was then removed by washing with deH2O and TBS-T followed by 
blocking the membrane with freshly prepared TBS-T + 5% skimmed dried milk for 1 
hr at room temperature with gentle agitation. 
 
 
Figure 2.1 Assembly of transfer sandwich for western blotting. 
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2.2.5.7 Immunodetection 
 
Following membrane blocking, the membrane was washed twice with TBS-T for 5 
mins and probed with 20 mL antibodies against caspase-3, -8, -9, PARP-1 and β-actin 
(Table 2.4) at 4 ºC overnight. After the overnight primary antibody incubation, the 
antibody was removed and kept at -20 ºC for future use. The membrane was taken 
through one complete cycle of washing steps with agitation: 1) TBS-T + 5% skimmed 
dried milk (15 mins); 2) TBS-T + 5% skimmed dried milk (2 x 5 mins); 3) TBS-T (15 
mins); 4) TBS-T (2 x 5 mins); and lastly 5) TBS (10 mins). The membrane was then 
incubated for 1 hr at room temperature with the 20 mL of the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibody (Table 2.4) under gentle agitation. 
Subsequently, the membrane was taken through another complete cycle of washing 
steps prior to being overlaid with 2 mL of the enhanced chemiluminescence (ECL) 
detection reagent for 1 min sealed with cling film at room temperature. The ECL 
detection reagent was drained off with a piece of filter paper. The membrane was then 
transferred on to a Li-Cor membrane reader faced-down, and trapped air bubbles were 
removed with a roller and analysed immediately.  
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Table 2.4 Dilutions of primary antibodies and secondary antibodies used for 
immunodetection. 
 
 
 
2.2.5.8 Membrane stripping and re-probing 
 
Membranes can be stripped and re-probed with another protein by gently stripping off 
the antibodies from the membrane. Following blot analysis, membrane was washed 
with TBS-T twice for 5 mins each. Membrane was incubated with membrane 
stripping buffer for 30 mins at 60 ºC with slight agitation every 10 mins interval. The 
membrane was washed with TBS-T four times for 5 mins each. Membrane was 
blocked with freshly prepared TBS-T + 5% skimmed dried milk for 1 hr at room 
temperature with gentle agitation. The blocked membrane was then taken through one 
complete cycle of washing step before re-probing with another primary antibody.  
 
 
 
 
 
 
Primary Antibodies (Host Species) Dilution 
Caspase-3 (Rabbit) 1:1,000 
Caspase-8 (Rabbit) 1:1,000 
Caspase-9 (Mouse) 1:1,000 
PARP-1 (Mouse) 1:1,000 
β-actin (Mouse) 1:5,000 
Secondary Antibodies (Host Species) Dilution 
Anti-rabbit-HRP 1:2,000 
Anti-mouse-HRP 1:2,000 
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2.2.6 Measurement of MMP 
 
Another distinct feature of apoptosis is the disruption of active mitochondria that 
leads to changes in the mitochondria membrane potential and altered oxidation-
reduction mitochondria potential. An intact mitochondrion actively transfers protons 
from the inner matrix to the intermembrane mitochondrial space creating a 
mitochondrial transmembrane potential (Δψm). Negative in the inner matrix and 
positive in the intermembrane space creating a Δψm of approximately 180 mV (Chen 
1988). The opening of the mitochondrial permeable transition pore in cells 
undergoing apoptosis allows passage of small molecules and ions, and results in 
depolarisation of the transmembrane potential, which is detectable using Δψm-
sensitive dyes. Tetramethylrhodamine, ethyl ester (TMRE), a positively charged, cell 
permeant, red-orange dye is able to accumulate within the mitochondria of healthy 
cells due to their relative negative charge. A decrease in the MMP and failure to 
sequester TMRE dye indicates inactive or depolarised mitochondria. Jurkat T cells (1 
x 105 cells) were treated with the IC50 concentrations and incubated at 37ºC for 24 hrs. 
Following treatment, TMRE at a final concentration of 0.2 µM was added to cells and 
incubated at 37 ºC protected from light for 30 mins. After incubation, the plate was 
centrifuged down at 3,500 rpm for 10 mins and washed with chilled PBS. 
Fluorescence readings were obtained on a fluorescence microplate reader (Tecan 
Infinite 200) with excitation and emission wavelengths of 549 nm and 575 nm 
respectively. TMRE accumulated in the mitochondria of normal cells with intact 
MMP exhibits high fluorescence intensity while a decrease in fluorescence intensity 
indicate cells with loss of MMP and are not able to accumulate TMRE in the 
mitochondria.  
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2.2.7 Determination of intracellular GSH levels 
 
The diminished cellular GSH levels in cells serve as an indicator of cellular oxidative 
stress. A common method used to determine the change in GSH levels in cells is via a 
cell permeable thiol probe, monochlorobimane (MCB) (Rice et al. 1986). MCB 
strongly fluoresce in blue when bound to reduced GSH. Jurkat T cells (5 x 104 cells/ 
well) were treated with the IC50 concentrations of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) and incubated in humidified atmosphere at 37ºC with 5% CO2 for 
24 hrs. After treatment, cells in the 96-well plate (5 x 104 cells/ well) were centrifuged 
and washed twice with 100 µL PBS at 3500 rpm for 10 mins. After the final wash, the 
supernatant was carefully removed and replaced with 100 µM of MCB in 100 µL 
PBS and incubated at 37 ºC for 30 mins in the dark. The GSH levels in the samples 
correlate with fluorescent intensity and was determined using a Tecan Infinite M200 
fluoro-plate reader with excitation and emission wavelengths of 390 nm and 460 nm, 
respectively. The appropriate blank, MCB in PBS alone, was subtracted from all the 
sample absorbance to obtain the corrected values. Percentage of intracellular GSH 
level was calculated using the formula as below: 
 
Intracellular GSH (%) =  
Fluorescence of treated cells − blank ×  100%
Fluorescence of untreated cells − blank
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2.2.8 Detection of ROS 
 
The production of ROS indicates the presence of oxidative damage in cells. 
Intracellular ROS was measured using an oxidant-sensitive fluorescent dye, 
dihydroethidium (DHE). This cell-permeable dye reacts with ROS to form a red 
fluorescent product, 2-hydroxyethidium, which intercalates with DNA. The 
fluorescence intensity is proportional to the amount of ROS generated (Cai et al. 
2007). Jurkat T cells (5 x 104 cells) were treated with the IC50 concentrations of 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) and incubated at 37ºC for 24 
hrs. Following treatment, cells in the 96-well plate (5 x 104 cells/ well) were 
centrifuged and washed twice with 100 µL PBS at 3,500 rpm for 10 mins. After the 
final wash, the supernatant was carefully removed and replaced with DHE at a final 
concentration of 10 µM in pre-warmed RPMI0 and incubated at 37 ºC for 30 mins in 
the dark. Cells were subsequently washed with cold PBS twice and re-suspended in 
100 µL PBS prior to measuring the fluorescence intensity using the Tecan Infinite 
M200 fluoro-plate reader with excitation and emission wavelengths of 535 nm and 
635 nm, respectively. The appropriate blank, DHE in RPMI0, was subtracted from all 
the sample absorbance to obtain the corrected values. 
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2.2.9 Determination of anti-oxidant effects on cell viability 
 
Anti-oxidants were used to determine the possible role of pro-oxidative cell death 
induced by cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on Jurkat T cells. 
Jurkat T cells (5 x 104 cells) were treated with the IC50 concentrations of cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II) in the presence or absence of anti-oxidants 
(1 mM NAC, 1 mM GSH, 1 mM Trolox, 1 mM L-cysteine or 1 mM D-cysteine) and 
incubated in humidified atmosphere at 37ºC with 5% CO2 for 24 hrs. Following 
treatment, the cell viability of Jurkat T cells was determined using the MTS cell 
viability assay as described in Section 2.2.2. 
 
2.3 Statistical Analysis 
 
The experimental data were analysed using a two-tailed distribution, paired, Student’s 
t-test where error bars indicate mean ± SEM  (n = 3 replicates) and representative of 
three independent experiments. Difference between the mean values where p < 0.05 
was considered significantly different.    
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CHAPTER 3: CYTOTOXICITY AND STRUCTURE 
ACTIVITY RELATIONSHIP OF CARDAMONIN 
DERIVATIVES AND COMPLEXES IN NORMAL AND 
CANCER CELL LINES 
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3.1 Introduction 
  
The chalcone, cardamonin, has attracted much attention for its ability to kill cancer 
cells (Murakami et al. 1993, Li et al. 2008, Simirgiotis et al. 2008, Dzoyem et al. 
2012, Kuete et al. 2014) among other biological properties. In an attempt to improve 
the anti-tumour activity of cardamonin, numerous derivatives and metal complexes 
were screened for their cytotoxic activity. The generation of natural product 
derivatives/ complexes remains an important goal to enhance bioactivity of a 
compound. To date, there are no methods for accurate prediction of biological activity 
of a designed compound and the processes largely rely on trial and error where 
knowledge and experience are advantageous. A quick and effective way to determine 
the bioactivity is through preliminary screening carried out using cell lines in vitro. In 
this chapter, the cytotoxicity of cardamonin and its derivatives were initially tested 
against the A549 epithelial cell line derived from human lung adenocarcinoma and 
HK1 squamous carcinoma from nasopharyngeal cancer cell lines. The influences of 
cardamonin structural modifications were discussed in relation to the cytotoxic 
activity as part of the SAR studies. Subsequently, the two most cytotoxic compounds 
were selected for further cytotoxicity studies against human normal MRC5 lung 
fibroblast cell line, human normal Hs68 foreskin fibroblast cell line and a leukaemic 
cell line, Jurkat T cell.   
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3.2 Results 
3.2.1 Cytotoxicity and the structure activity relationship of cardamonin and its 
derivatives on human A549 and HK1 carcinoma cell lines  
 
Initial studies were carried out to determine the cytotoxicity of cardamonin and its 
derivatives in human A549 lung and human HK1 nasopharyngeal carcinoma cell lines 
where the IC50 values were obtained at 24, 48 and 72 hrs treatment as summarised in 
Table 3.1. Figures 3.1 - 3.21 present the dose response curves for each compound. 
An overall comparison on the cytotoxicity of cardamonin and its derivatives in A549 
and HK1 cancer cell lines revealed a hint of selectivity towards HK1 cells making this 
cell line more susceptible to treatment compared to A549 cells. Between cardamonin 
and its 20 derivatives, only six of the compounds were more cytotoxic to A549 cells, 
having lower IC50 values compared to HK1 cells. These six compounds include urea-
cardamonin (Figure 3.14), cardamonin-B (Figure 3.4), cardamonin-I(II) (Figure 
3.19), cardamonin-Br(II) (Figure 3.20), and benzoyl-cardamonin (Figure 3.21). 
However, there are no apparent structural correlations that can be observed among 
these six compounds that could account for the difference seen in A549 cells being 
more susceptible. This selectivity towards HK1 cells suggests that A549 cells are 
more resistant. Compounds cardamonin-Cu(II) (Figure 3.2) and cardamonin-Fe(II) 
(Figure 3.3) exhibited the two highest cytotoxic activity in the two cancer cell lines. 
IC50 values over 24, 48 and 72 hrs treatment ranged from 17.3 to 58.3 µM in A549 
cells and 0.76 to 9 µM in HK1 cells for cardamonin-Cu(II); and 22.7 to 38.0 µM in 
A549 cells and 16.6 to 23.2 µM in HK1 cells for cardamonin-Fe(II) as summarised in 
Table 3.1. These results indicated that complexing cardamonin to metal complexes 
such as copper and iron can increase the cytotoxic activity significantly. Cardamonin-
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Cu(II) in particular decreased the cell viability of HK1 by more than ten-fold 
compared to the parent compound, cardamonin, at all the time points. The less 
effective compounds with IC50 >200 µM in both cell lines were OMe-cardamonin 
(Figure 3.11), hydroxylamine-cardamonin (Figure 3.13), thiourea-cardamonin 
(Figure 3.15), tetrahydro-cardamonin (Figure 3.16) and flavanone-cardamonin 
(Figure 3.18). Interestingly, replacing both the hydroxyl groups of cardamonin with 
hydrophobic groups, OBn and OMe, in OBn-cardamonin (Figure 3.10) and OMe-
cardamonin (Figure 3.11) respectively resulted in a loss of cytotoxicity in both cell 
lines. However, the cytotoxicity was enhanced upon the addition of the less 
hydrophobic allyl group to allyl-cardamonin (Figure 3.7). Loss of the carbonyl group 
in both phenylamine-cardamonin (Figure 3.9) and methoxyamine-cardamonin 
(Figure 3.8) resulted in significantly less cytotoxicity in both cell lines. Conversely, 
the loss of carbonyl group in cardamonin-B (Figure 3.4) resulted in an increased 
cytotoxicity compared to the parent compound in both cell lines, highlighting that 
modifications to the carbonyl group significantly alter the cytotoxicity effect. 
Compounds hydroxylamine-cardamonin and hydrazinium-cardamonin possessed very 
similar structures. Instead of an alkene group linking the two benzene rings in 
cardamonin, hydroxylamine functional group and hydrazinium connect the two 
benzene rings in hydroxylamine-cardamonin and hydrazinium-cardamonin 
respectively. Interestingly, these two compounds exhibited very different cytotoxic 
activities. Hydroxylamine-cardamonin (Figure 3.13) is one of the weakest compound 
with IC50 >200 µM tested in both cells lines whereas the IC50 of hydrazinium-
cardamonin (Figure 3.5) was ≥80 µM in both cell lines. This data demonstrated that 
the position of the alkene group also has an important influence on the cytotoxicity of 
these compounds. Evidently, replacement of the alkene group with methylene bridge 
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in tetrahydro-cardamonin (Figure 3.16) resulted in a total loss of cytotoxicity in both 
cell lines with IC50 >200 µM at all the time points examined. Additionally, both urea-
cardamonin (Figure 3.14) and thiourea-cardamonin (Figure 3.15) have very similar 
structures except that the oxygen atom of urea in urea-cardamonin is replaced by a 
sulphur atom in thiourea-cardamonin linking the two benzene rings. The replacement 
of oxygen with sulphur atom results in a loss of cytotoxicity in both cell lines as seen 
in thiourea-cardamonin. On the other hand, introduction of urea group to the 
cardamonin structure showed better activity towards both cell lines compared to the 
parent compound. With regards to the effect of hydroxyl groups at position 2 and 4 on 
cytotoxic activity of cardamonin, results illustrate that loss of both hydroxyl groups 
altered the cytotoxicity of cardamonin. The two additional methyl group and carbonyl 
group replacing the hydroxyl groups in acetyl-cardamonin (Figure 3.6) greatly 
increased the cytotoxicity in both cell lines. Whereas the fluoro-benzene derivative of 
cardamonin, 4-fluoro-cardamonin (Figure 3.12) resulted in a loss of cytotoxicity in 
both cell lines compared to acetyl-cardamonin. This data suggest that the improved 
cytotoxicity observed in acetyl-cardamonin is due to the substitution of fluoro-
benzene rings with methyl groups at position 2. Comparing flavanol-cardamonin 
(Figure 3.17) and flavanone-cardamonin (Figure 3.18), the removal of three 
hydroxyl groups in flavanone-cardamonin resulted in a drop of cytotoxicity in both 
cell lines compared to flavanol-cardamonin. This is in contrast to the conclusion 
drawn from above where a decrease in cardamonin hydroxyl groups increases the 
cytotoxicity. It is however important to note that the introduction of the three 
additional hydroxyl groups in flavanol-cardamonin was at different positions. 
Therefore, the position of the hydroxyl groups was proven to be a greater factor in 
affecting the cytotoxic activities of the tested compounds compared to the number of 
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hydroxyl groups present in the compounds. Two halogen elements, iodine and 
bromine, were bonded to cardamonin at position 5 resulting in compounds 
cardamonin-I(II) and cardamonin-Br(II) respectively. Cardamonin-I(II) (Figure 3.19) 
showed much higher cytotoxic activity than that of cardamonin-Br(II) (Figure 3.20) 
in both cancer cell lines. This finding further suggest that the C5 position on the 
benzene ring of cardamonin also has an important influence on the cytotoxicity of 
these compounds.  
 
 In the present study, cardamonin and its 20 derivatives were initially tested in 
human lung cancer A549 and nasopharyngeal cancer HK1 cell lines. The SAR 
analyses suggested that the cytotoxic activities of diverse cardamonin derivatives was 
affected by a range of factors including the modification of hydroxyl group, presence 
of alkene group, addition of chemical groups, with the greatest cytotoxicity advantage 
being complexing with metal ions. 
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A 
 
B 
Figure 3.1 Effect of cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with cardamonin for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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A 
  
B
 
Figure 3.2 Effect of cardamonin-Cu(II) in cancer human cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with cardamonin-Cu(II) for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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A 
 
B 
 
Figure 3.3 Effect of cardamonin-Fe(II) in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with cardamonin-Fe(II) for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.4 Effect of cardamonin-B in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with cardamonin-B for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.5 Effect of hydrazinium-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with hydrazinium-cardamonin for 24, 48 and 72 hrs and cell 
viability was assessed via the MTS assay as outlined in the Materials and Methods 
section. Results are means ± SEM of three independent experiments. 
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Figure 3.6 Effect of acetyl-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with acetyl-cardamonin for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.7 Effect of allyl-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with allyl-cardamonin for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.8 Effect of methoxyamine-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with methoxyamine-cardamonin for 24, 48 and 72 hrs and cell 
viability was assessed via the MTS assay as outlined in the Materials and Methods 
section. Results are means ± SEM of three independent experiments. 
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Figure 3.9 Effect of phenylamine-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with phenylamine-cardamonin for 24, 48 and 72 hrs and cell 
viability was assessed via the MTS assay as outlined in the Materials and Methods 
section. Results are means ± SEM of three independent experiments. 
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Figure 3.10 Effect of OBn-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with OBn-cardamonin for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.11 Effect of OMe-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with OMe-cardamonin for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.12 Effect of 4-fluoro-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with 4-fluoro-cardamonin for 24, 48 and 72 hrs and cell viability 
was assessed via the MTS assay as outlined in the Materials and Methods section. 
Results are means ± SEM of three independent experiments. 
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Figure 3.13 Effect of hydroxylamine-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with hydroxylamine-cardamonin for 24, 48 and 72 hrs and cell 
viability was assessed via the MTS assay as outlined in the Materials and Methods 
section. Results are means ± SEM of three independent experiments. 
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Figure 3.14 Effect of urea-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with urea-cardamonin for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.15 Effect of thiourea-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with thiourea-cardamonin for 24, 48 and 72 hrs and cell viability 
was assessed via the MTS assay as outlined in the Materials and Methods section. 
Results are means ± SEM of three independent experiments. 
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Figure 3.16 Effect of tetrahydro-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with tetrahydro-cardamonin for 24, 48 and 72 hrs and cell viability 
was assessed via the MTS assay as outlined in the Materials and Methods section. 
Results are means ± SEM of three independent experiments. 
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Figure 3.17 Effect of flavanol-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with flavanol-cardamonin for 24, 48 and 72 hrs and cell viability 
was assessed via the MTS assay as outlined in the Materials and Methods section. 
Results are means ± SEM of three independent experiments. 
 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
0 10 20 30 40 50 60 70 80 90 100 110 
C
el
l 
V
ia
b
il
it
y
 (
%
) 
Concentration (µM) 
Flavanol-cardamonin complex against human A549 lung cancer cell line  
24 hrs 
48 hrs 
72 hrs 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
0 10 20 30 40 50 60 70 80 90 100 110 
C
el
l 
V
ia
b
il
it
y
 (
%
) 
Concentration (µM) 
Flavanol-cardamonin complex against  
human HK1 nasopharyngeal cancer cell line  
24 hrs 
48 hrs 
72 hrs 
81 
 
A 
 
B 
 
Figure 3.18 Effect of flavanone-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with flavanone-cardamonin for 24, 48 and 72 hrs and cell viability 
was assessed via the MTS assay as outlined in the Materials and Methods section. 
Results are means ± SEM of three independent experiments. 
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Figure 3.19 Effect of cardamonin-I(II) in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with cardamonin-I(II) for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.20 Effect of cardamonin-Br(II) in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with cardamonin-Br(II) for 24, 48 and 72 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. 
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Figure 3.21 Effect of benzoyl-cardamonin in human cancer cell lines. 
Human A549 lung cancer cells (A) and human HK1 nasopharyngeal cancer cells (B). 
Cells were treated with benzoyl-cardamonin for 24, 48 and 72 hrs and cell viability 
was assessed via the MTS assay as outlined in the Materials and Methods section. 
Results are means ± SEM of three independent experiments. 
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Table 3.1 IC50 values of cardamonin and its derivatives in human lung A549 and human nasopharyngeal cancer HK1 cell lines following 
24, 48 and 72 hrs treatment. 
 
 
Compounds 
A549, IC50 (µM) HK1, IC50 (µM) 
24 hrs 48 hrs 72 hrs 24 hrs 48 hrs 72 hrs 
Cardamonin >200 110.4 67.0 92.7 54.8 22.6 
Acetyl-
cardamonin 
69.7 41.2 33.6 55.2 40.1 33.4 
Allyl-
cardamonin 
152.5 101.5 35.1 59.3 21.6 4.95 
OBn-
cardamonin 
>200 >200 >200 >200 >200 150.3 
OMe-
cardamonin 
>200 >200 >200 >200 >200 >200 
Cardamonin-
Cu(II) 
58.3 47.1 17.3 9.0 3.7 0.76 
Cardamonin-
Fe(II) 
38.0 
 
26.0 
 
22.7 
 
23.2 
 
22.5 
 
16.6 
 
Cardamonin-B 40.9 30.2 23.9 52 53 36.6 
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Benzoyl-
cardamonin 
61.7 48.8 37.6 68.4 58.0 29.4 
Phenylamine-
cardamonin 
>200 >200 >200 >200 >200 139 
Methoxyamine
-Cardamonin 
>200 >200 >200 >200 >200 140 
Hydroxylamine
-Cardamonin 
>200 >200 >200 >200 >200 >200 
Urea-
cardamonin 
50.2 45.9 29.9 102.5 75.4 66.5 
Thiourea-
cardamonin 
>200 >200 >200 >200 >200 >200 
4-fluoro-
cardamonin 
134.8 121.41 106.4 170.5 104.2 89.5 
Tetrahydro-
cardamonin 
>200 >200 >200 >200 >200 >200 
Flavanol-
cardamonin 
85.8 101.2 106.0 >200 166.0 57.2 
Flavanone-
cardamonin 
>200 >200 >200 >200 >200 >200 
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5-Iodo-
cardamonin 
46.4 42.2 36.1 85.1 73.0 49.7 
5-Bromo-
cardamonin 
135.86 164 186 >200 >200 >200 
Hydrazinium-
cardamonin 
80.4 77.3 63.8 54.1 58.6 46.8 
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3.2.2 Cytotoxicity of cardamonin and its complexes assessed in normal human MRC5 
and Hs68 cell lines 
 
As previously shown in Table 3.1, compounds cardamonin-Cu(II) and cardamonin-
Fe(II) overall exhibited the two highest cytotoxic activity in A549 and HK1 cell lines. 
IC50 values ranged from 17 to 58 µM in A549 cells and 0.76 to 9 µM in HK1 cells for 
cardamonin-Cu(II); 22 to 38 µM in A549 cells and 16 to 23 µM in HK1 cells for 
cardamonin-Fe(II).  
 
Based on these results, the two complexes and the parent compound, 
cardamonin, were further assessed for their cytotoxicity in normal human lung MRC5 
and normal human foreskin Hs68 cell lines for 24 hrs to determine whether the 
cytotoxicity of these compounds were selective towards carcinoma cell lines. 
  
 Figures 3.22 - 3.24 display the dose response curves for each compound. 
Table 3.2 summarise the IC50 values of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) in MRC5 and Hs68 lines following 24 hrs treatment. The cytotoxic 
effectiveness in order of decreasing IC50 values for both MRC5 and Hs68 lines were 
as follow: cardamonin (Figure 3.22) < cardamonin-Fe(II) (Figure 3.24) < 
cardamonin-Cu(II) (Figure 3.23). This order of effectiveness was observed in all cell 
lines tested with the exception of A549 cell line where cardamonin-Fe(II) appeared 
more cytotoxic compared to cardamonin-Cu(II) and cardamonin was again least 
cytotoxic.  
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A direct comparison of IC50 values between A549 lung carcinoma cell line 
and MRC5 lung normal cell line revealed the normal cells were more susceptible to 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) suggesting these compounds 
are not only cytotoxic towards carcinoma cells (Table 3.2). However, Hs68 cells were 
less sensitive towards these compounds implying some level of selectivity from 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) depending on the type of cells 
exposed to. 
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Figure 3.22 Effect of cardamonin in normal human cell lines. 
Human MRC5 lung cells (A) and human Hs68 foreskin cells (B). Cells were treated 
with cardamonin for 24 hrs and cell viability was assessed via the MTS assay as 
outlined in the Materials and Methods section. Results are means ± SEM of three 
independent experiments. 
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Figure 3.23 Effect of cardamonin-Cu(II) in normal human cell lines. 
Human MRC5 lung cells (A) and human Hs68 foreskin cells (B). Cells were treated 
with cardamonin-Cu(II) for 24 hrs and cell viability was assessed via the MTS assay 
as outlined in the Materials and Methods section. Results are means ± SEM of three 
independent experiments. 
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A 
 
B 
 
Figure 3.24 Effect of cardamonin-Fe(II) in normal human cell lines. 
Human MRC5 lung cells (A) and human Hs68 foreskin cells (B). Cells were treated 
with cardamonin-Fe(II) for 24 hrs and cell viability was assessed via the MTS assay 
as outlined in the Materials and Methods section. Results are means ± SEM of three 
independent experiments. 
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Table 3.2 Summary of the IC50 values in human lung cancer A549, human 
nasopharyngeal cancer HK1, human normal MRC5 lung, human normal Hs68 
foreskin cell lines following 24 hrs treatment. 
Compounds 
A549, 
IC50 (µM) 
HK1, 
IC50 (µM) 
MRC5, 
IC50 (µM) 
Hs68, 
IC50 (µM) 
Cardamonin >100 94.7 47.0 >100 
Cardamonin-Cu(II) 58.3 9.0 19.79 70.5 
Cardamonin-Fe(II) 38.0 23.2 30.1 89.9 
 
Selectivity index was further calculated to determine the level of selectivity of 
active derivatives towards cancer cell lines compared to normal cell lines. Table 3.3 
showed cardamonin-Cu(II) selectivity index was greatest in HK1 nasopharyngeal 
cancer cell lines with highest value of 7.83, indicating this compound is more than 
seven times more cytotoxic to the HK1 cancer cell line compared to Hs68 normal cell 
line. Data also revealed the complexes were less cytotoxic to Hs68 normal foreskin 
cell line compared to MRC5 normal lung cell line. Furthermore, it was not possible to 
obtain the selectivity index of cardamonin, since this compound was more cytotoxic 
to the normal lung cell lines compared to the cancer cell lines tested. Similarly, 
cardamonin-Cu(II) and cardamonin-Fe(II) treatments were more cytotoxic to normal 
lung cell line compared to the cancer lung cell line. Hence, the selectivity index value 
was unattainable. 
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Table 3.3 Selectivity of the cytotoxicity of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) to A549 lung and HK1 nasopharyngeal cancer cell lines as 
compared with MRC5 lung and HS68 foreskin normal cell lines. 
Compounds 
MRC5 selectivity index Hs68 selectivity index 
A549 HK1 A549 HK1 
Cardamonin NA NA NA NA 
Cardamonin-Cu(II) NA 2.2 1.21 7.83 
Cardamonin-Fe(II) NA 1.30 2.37 3.88 
Selectivity index = (IC50 of normal cells) / (IC50 of A549 or HK1 cancer cells) 
 
3.2.3 Cytotoxicity of cardamonin and its complexes assessed in human Jurkat T cells 
 
Since cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) were found to be toxic 
in normal cells, specifically the MRC5 lung cell line, we next investigate the 
cytotoxicity of these compounds in Jurkat T leukaemic cells, a commonly used cell 
line in determining the mechanism of differential susceptibility to drugs (Howe 2016). 
Figure 3.25 display the dose response curves for each compound. As summarised in 
Table 3.4, Jurkat T cells were most susceptible following 24 hrs treatment compared 
to all other cell lines tested. IC50 values were lowest in Jurkat T cells across all three 
compounds tested at 37.6, 7.9 and 17.4 µM for cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II), respectively. As shown in Figure 3.25, all three compounds 
induced a dose-dependent decrease in Jurkat T cell viability.  
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Figure 3.25 Effect of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) in 
human Jurkat T cells. 
Cells were treated with cardamonin (A), cardamonin-Cu(II) (B) and cardamonin-
Fe(II) (C) for 24 hrs and cell viability was assessed via the MTS assay as outlined in 
the Materials and Methods section. Results are means ± SEM of three independent 
experiments. 
 
Table 3.4 Summary of the IC50 values in human lung cancer A549, human 
nasopharyngeal cancer HK1, human normal MRC5 lung, human normal Hs68 
foreskin and Jurkat T cell lines following 24 hrs treatment. 
Compounds A549, 
IC50 (µM) 
HK1, 
IC50 (µM) 
MRC5, 
IC50 (µM) 
Hs68, 
IC50 (µM) 
Jurkat T, 
IC50 (µM) 
Cardamonin >100 94.7 47.0 >100 37.6 
Cardamonin-Cu(II) 58.3 9.0 19.79 70.5 7.9 
Cardamonin-Fe(II) 38.0 23.2 30.1 89.9 17.4 
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3.3 Discussion 
 
The cytotoxicity was initially assessed for all 20 cardamonin derivatives including 
cardamonin using human A549 lung and human HK1 nasopharyngeal cell lines. All 
cardamonin derivatives were tested at the same concentration and incubated under 
constant conditions. The colorimetric MTS assay was used to assess compounds’ 
cytotoxicity and results were expressed as IC50 values representing the concentration 
of a compound with half-maximal cell viability compared to the untreated control.  
 
 Cardamonin-Cu(II) and cardamonin-Fe(II) complexes were the two most 
cytotoxic derivatives of cardamonin. According to Graf and Lippard (2012), various 
synthetic and natural drugs require the activation by metal ions acting as pro-drugs in 
the body. A review on metal-mediated drugs has suggested that metal ions are able to 
coordinate with natural or organic compounds providing advantages over the original 
drugs themselves (Tang and Liang 2013). As seen in this study, both cardamonin-
Cu(II) and cardamonin-Fe(II) complexes improved cytotoxicity which could be due to 
copper and iron both having variable oxidation states and therefore are involved in the 
redox reactions. They donate or accept electrons and initiate the reduction-oxidation 
reactions. The metal ions can function to generate reactive species in redox reaction 
and facilitate binding in catalysis (Petrucci et al. 2002).  
 
 Recently, copper metal ions were used as a potential delivery agent for the 
anti-cancer drug taxol (Manning et al. 2014). The efficacy of copper-taxol and 
copper-taxol-hydroxychloroquin complexes was compared to pure taxol (Manning et 
al. 2013). The researchers reported the complexation of the copper ions to taxol 
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improved the efficacy of taxol in a range of cell lines studied. Manning et al. (2014) 
also suggested that copper ions might have promising applications as a cancer drug as 
they have the ability to improve water solubility of drugs and stabilise a drug 
structure. As for iron metal ions, they have been reported in some studies to cause 
DNA cleavage by forming a complex with a drug that is further activated by the 
reaction with oxygen (Hecht 1986, Stubbe and Kozarich 1987, Chen and Stubbe 
2005).   
  
 Overall, the cytotoxicity of cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes was related to inhibition of certain specific processes in the cells. Further 
studies are required to understand better the mechanisms of bioactivity for these 
compounds. The following study examined the cytotoxicity of cardamonin-Cu(II) and 
cardamonin-Fe(II) complexes in normal human cell lines to determine whether these 
novel compounds were only selective towards cancer cells. A direct comparison of 
IC50 values between A549 lung carcinoma cell line and MRC5 lung normal cell line 
revealed the normal cells were more susceptible to cardamonin, cardamonin-Cu(II) 
and cardamonin-Fe(II) suggesting these compounds are not only cytotoxic towards 
carcinoma cells. However, Hs68 cells were less sensitive towards these compounds 
implying some level of selectivity from cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) depending on the type of cells exposed to. 
 
 Subsequently, Jurkat T cells were found to be most susceptible to cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II) treatment compared to all other cell lines 
tested. The high susceptibility of Jurkat T cells to these compounds may be due to the 
state of the cells being in suspension form, while all other cell lines tested were 
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adherent cells. Furthermore, chalcones have been reported to be particularly cytotoxic 
towards leukaemic cell lines (Dimmock et al. 1998, Maioral et al. 2013). Generally, 
the data in this chapter demonstrated that the generation of cardamonin derivatives 
and complexes resulted in enhanced cytotoxicity in several of these compounds, 
particularly cardamonin-Cu(II) and cardamonin-Fe(II) complexes. These results 
indicated that complexing cardamonin to metal complexes such as copper and iron 
increased the cytotoxic activity significantly.  
 
 Overall, cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes 
were found to be cytotoxic in normal lung A549 cell line but less cytotoxic in normal 
foreskin Hs68 cell line. Following 24 hrs treatment, the increased resistance in order 
of increasing IC50 values for cardamonin were as follow: Jurkat T < MRC5 < HK1 < 
A549 = Hs68; for cardamonin-Cu(II) complex: Jurkat T < HK1 < MRC5 < A549 < 
Hs68; and for cardamonin-Fe(II) complex: Jurkat T < HK1 < MRC5 < A549 < Hs68. 
On the whole, Jurkat T cells were most sensitive to all three treatments. As previous 
studies have shown that chalcones are particularly cytotoxic towards leukaemic cell 
lines, the following chapter explores the differential susceptibility of adherent and 
suspension cells towards cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II).  
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CHAPTER 4: THP-1-DERIVED MACROPHAGES 
INCREASED RESISTANCE TOWARDS CARDAMONIN, 
CARDAMONIN-Cu(II) AND CARDAMONIN-Fe(II) 
COMPLEXES WERE INDEPENDENT OF P38α AND 
P38β MAP KINASE PATHWAY 
  
101 
 
4.1 Introduction  
 
As illustrated in Chapter 3, cardamonin and its derivatives/ complexes induced cell 
death at different sensitivity depending on the different cell origin. Compared to both 
cancer and normal adherent cell lines tested, the suspension Jurkat T cells were most 
sensitive to cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes. This 
difference in cell susceptibility between adherent and suspension cell lines is 
particularly interesting and should be further investigated as a number of studies have 
also reported that suspension cells are more susceptible to inhibition of cell growth 
compared to adherent cells (Dimmock et al. 1998, Kimura et al. 2004, Daigneault et 
al. 2010, Maioral et al. 2013). Moreover, studies have shown an increase in survival 
signals in adherent cells compared to suspension cells (Kohro et al. 2004). The 
present study was initiated to examine the differential susceptibility between 
suspension and adherent cells as well as the changes in cell susceptibility following 
inhibition of a key survival signal in adherent cells. Since the susceptibility of the 
suspension and adherent cells previously tested in this study are from a range of 
different tissue origin, a true comparison cannot be established due to the different 
characteristics and diverse receptor expressions of the different cell lines. Hence, in 
this study, THP-1 cells were used as our experimental model since this particular cell 
line can be cultured in both suspension and adherent phase. Considering these cells 
were derived from the same tissue origin, the susceptibility studies will be more 
comparable. Also, matured macrophages are known to mediate signaling mechanism 
that involves mitogen-activated protein (MAP) kinase activation (Traore et al. 2005). 
This chapter will explore the effects of interference from inhibitors of p38α and p38β 
MAP kinase on differentiated mature THP-1 macrophages compared to monocytes. 
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4.2 Results 
4.2.1 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on THP-1 cell 
viability  
 
Initial studies were carried out to examine the cytotoxic effect of cardamonin, 
cardamonin-Cu(II) complex and cardamonin-Fe(II) complex on THP-1 monocytes. A 
dose response curve was obtained following 24 hrs treatment with cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II) at concentrations ranging from 6.25 µM to 
100 µM. Control cells were not treated with any compounds. Results reveal, THP-1 
cell viability decreased in a dose-dependent manner following treatment with all three 
compounds tested. Cardamonin-Cu(II) complex was more cytotoxic to THP-1 cells 
compared to cardamonin and cardamonin-Fe(II) treatment. Results in Figure 4.1 
demonstrate Cardamonin-Cu(II) caused a drastic decrease in cell viability from 92% 
to 13%  when exposed to treatment concentrations from 6.25 µM to 100 µM for 24 
hrs. THP-1 cell viability decreased dose-dependently from 99% to 51% when exposed 
to cardamonin-Fe(II) concentrations ranging from 6.25 µM to 100 µM for 24 hrs. 
THP-1 cells were least sensitive towards cardamonin treatment, where cells 
maintained >70% in cell viability after 24 hrs treatment. Taken together, a similar 
cytotoxicity trend was observed with Jurkat T cells where cardamonin-Cu(II) and 
cardamonin-Fe(II) were more active than the parent compound with cardamonin 
being least cytotoxic and cardamonin-Cu(II) being most cytotoxic. 
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Figure 4.1 Effect of cardamonin, cardamonin-Cu(II) complex and cardamonin-
Fe(II) complex on THP-1 monocytes cell viability.  
THP-1 cells were exposed to various concentrations (6.25, 12.5, 25, 50 and 100 µM) 
of cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) complex for 24 
hrs. The MTS assay was used to assess cell viability as described in the Materials and 
Methods section. Results were expressed as mean ± SEM from three independent 
experiments. 
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4.2.2 Morphological changes in THP-1 monocytes differentiation to macrophages  
 
In an effort to investigate the differential susceptibility between suspension and 
adherent cells, THP-1 monocytes were differentiated in to macrophages by 
stimulating the cells with PMA. THP-1 cells were treated with PMA up to five days 
and the morphological changes were observed every 24 hrs using a phase contrast 
microscopy (Figure 4.2). As seen in Figure 4.2A, non-stimulated THP-1 monocytes 
appear rounded and floated in the medium. These spherical cells were more regular 
morphologically and appear homogenous. Following 24 hrs PMA-stimulation (Figure 
4.2B), more than 80% of the cells started to adhere but was loosely attached to the 
culture flask. Only 10-20% of the cells appear to spread out with spindle-like shapes 
and was morphologically irregular. After 48 hrs of exposure to PMA (Figure 4.2C), 
almost all of the cells have adhered firmly to the culture flask excluding any dead 
cells and cell debris. Approximately 50% of the cells have now developed into 
fibroblast-like cells with spindles spreading from the cells with a lesser mix 
population of rounded cells. By 72 hrs (Figure 4.2D), more than 90% of the cells 
exhibited significant morphology change exhibiting long and thin body similar to 
fibroblast-like cells. The cells were more defined and appeared flattened, well spread, 
attaching very firmly to the culture flask. Following 96 hrs (Figure 4.2E) and 120 hrs 
(Figure 4.2F) treatment, cells appear to shrink and start to detach from the culture 
flasks respectively. Prolonged PMA stimulation of more than 72 hrs could be toxic to 
THP-1 cells leading to progression to unhealthy macrophages. Hence, 72 hrs 
treatments were used for subsequent experiments involving THP-1-derived 
macrophages. 
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(A) THP-1 monocytes 
 
  (B) PMA 24 hrs 
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  (C) PMA 48 hrs 
 
  (D) PMA 72 hrs 
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  (E) PMA 96 hrs 
 
  (F) PMA 120 hrs 
 
Figure 4.2 Cellular morphology of THP-1 monocytes and PMA-induced 
differentiation to THP-1-derived macrophages.  
Non-stimulated THP-1 monocytes (A) and 50 ng/mL PMA-stimulated for 24 hrs (B), 
48 hrs (C), 72 hrs (D), 96 hrs (E) and 120 hrs (F) were observed using a phase 
contrast microscopy. Indication of arrows: white indicates non-stimulated THP-1 
monocytes; yellow indicates loosely attached pre-mature THP-1 cells; green indicates 
well-defined, flatten, fibroblast-like cells; and red indicates shrinkage, clumping and 
loss of cell membrane integrity cells. Results shown are one representation from three 
independent experiments. Original magnification x200. 
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4.2.3 Expression of CD11b surface marker 
 
Apart from morphological changes, maturation of THP-1 cells to mature macrophages 
can be further assessed. Following 72 hrs stimulation of THP-1 cells to 50 ng/mL 
PMA, cells were subjected for further analysis using specific cell surface markers, 
CD11b. CD11b, an α-subunit of β2 integrin is up-regulated in differentiated THP-1-
derived macrophages (Mittar et al. 2011). Results in Figure 4.3 revealed unstained 
and isotype control of both THP-1 and THP-1 macrophages have low fluorescence 
intensity. By contrast, following 72 hrs of 50 ng/mL PMA treatment, there was a 
positive shift in mature THP-1 macrophages expressing CD11b. These data further 
confirms that the THP-1 cells have successfully differentiated to mature macrophages.  
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Figure 4.3 Expression of CD11b surface markers in THP-1 monocytes and THP-
1-derived macrophages. 
THP-1-derived macrophages were differentiated with 50 ng/mL PMA for 72 hrs.  
Fluorescence intensity histogram of unstained (A), mouse IgG1 isotype control 
stained (B) and FITC-anti CD11b stained samples (C) of THP-1 monocytes; and 
unstained (D), mouse IgG1 isotype control stained (E) and FITC-anti CD11b stained 
samples of (F) of THP-1-derived macrophages. 
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4.2.4 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on THP-1-
derived macrophages cell viability 
 
Once THP-1 monocytes have been differentiated to mature macrophages, the 
cytotoxicity of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
THP-1-derived macrophages cell viability was examined. Results reveal, the cell 
viability of THP-1-derived macrophages decreased in a dose-dependent manner 
following treatment with cardamonin-Cu(II) complex. However, cardamonin and 
cardamonin-Fe(II) complex had minimal effect on the viability of THP-1-derived 
macrophages. Cardamonin-Cu(II) complex was most cytotoxic to THP-1-derived 
macrophages compared to cardamonin and cardamonin-Fe(II) treatment. Results in 
Figure 4.4 demonstrate Cardamonin-Cu(II) caused a decrease in cell viability from 
90% to 33% when exposed to treatment concentration from 6.25 µM to 100 µM for 
24 hrs. The macrophages maintained >90% and >80% in cell viability in the presence 
of cardamonin and cardamonin-Fe(II) respectively, even at the highest concentration 
tested, 100 µM. An interesting trend was observed across all THP-1-derived 
macrophages compared to THP-1 monocytes where the macrophages were 
comparatively more resistant to all three treatments suggesting that monocytes were 
indeed more susceptible to treatment. A similar trend to the THP-1 monocytes and 
Jurkat T cells was observed where the order of cytotoxicity was cardamonin < 
cardamonin-Fe(II) < cardamonin-Cu(II) with IC50 values of >100, >100 and 40 µM 
respectively. Collectively, these results confirm that differentiation of THP-1 
monocytes to macrophages indeed reduced the susceptibility and increase some 
resistance towards cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes-
induced cell death.  
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Figure 4.4 Effect of cardamonin, cardamonin-Cu(II) complex and cardamonin-
Fe(II) complex on THP-1-derived macrophages cell viability.  
THP-1-derived macrophages were exposed to various concentrations (6.25, 12.5, 25, 
50 and 100 µM) of cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) 
complex for 24 hrs. The MTS assay was used to assess cell viability as described in 
the Materials and Methods section. Results were expressed as mean ± SEM from 
three independent experiments. 
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4.2.5 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on THP-1-
derived macrophages cell viability in the presence of a MAP kinase inhibitor, p38 
MAP kinase inhibitor IV 
 
Subsequent to observing an increased resistance towards treatment following the 
differentiation of THP-1 monocytes to macrophages, efforts were made to determine 
the possible correlation of the differential susceptibility. In order to dissect the 
possible signaling network causing a change in cell viability from THP-1 monocytes 
to macrophages, a chemical inhibitor was used. A MAP kinase inhibitor specific in 
blocking p38α and p38β (Figure 4.5) was added to THP-1-derived macrophages prior 
to treatment with cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) 
complex. This inhibitor was introduced to THP-1-derived macrophages in order to 
evaluate whether the perceived differential susceptibility was associated with 
activation of p38 MAP kinase. The cytotoxic effect on cell viability of p38 MAP 
kinase inhibited-THP-1-derived macrophages (p38inTHP-1-derived macrophages) of 
cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) complex was 
assessed. Figure 4.6A shows the effect of cardamonin, cardamonin-Cu(II) complex 
and cardamonin-Fe(II) complex on p38inTHP-1-derived macrophages following 24 
hrs treatment. Results revealed, similar to THP-1-derived macrophages, cells 
maintained their viability >90% after cardamonin treatment on p38inTHP-1-derived 
macrophages. Like both THP-1 monocytes and THP-1-derived macrophages, 
p38inTHP-1-derived macrophages was most susceptible to cardamonin-Cu(II) 
complex. p38inTHP-1-derived macrophages treatment with cardamonin-Fe(II) 
complex appeared to show similar effects on cell viability as THP-1-derived 
macrophages. Cell viability maintained above 80% at the highest concentration of 
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cardamonin-Fe(II) complex tested. Overall, these findings appear to suggest that p38α 
and p38β MAP kinase signaling pathway was not mainly responsible for the THP-1-
derived macrophages differential susceptibility observed when treated with 
cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) complex.  
 
 
Figure 4.5 p38 MAP kinase inhibitor IV. Synonym: 2,2’-Sulfonyl-bis-(3,4,6-
trichlorophenol). 
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Figure 4.6 Effect of cardamonin, cardamonin-Cu(II) complex and cardamonin-
Fe(II) complex on THP-1-derived macrophages cell viability in the presence of a 
MAP kinase inhibitor, p38 MAP kinase inhibitor IV.  
THP-1-derived macrophages were exposed to various concentrations (6.25, 12.5, 25, 
50 and 100 µM) of cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) 
complex in the presence of 1 µM p38 MAP kinase inhibitor for 24 hrs. The MTS 
assay was used to assess cell viability as described in the Materials and Methods 
section. Results were expressed as mean ± SEM from three independent experiments. 
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4.2.6 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on THP-1-
derived macrophages cell viability in the presence of a MAP kinase inhibitor, 
SB202190 MAP kinase inhibitor  
 
To validate the above findings, a second inhibitor of the p38 MAP kinase was used, 
SB202190 (Figure 4.7) as Davies et al. (2000) highlighted the importance of using at 
least two structurally unrelated inhibitors for cell-based assays. Previous study has 
shown that SB202190 by itself was able to induce cell death (Nemoto et al. 1998). 
The recommended concentration of 10 µM (Arana-Argáez et al. 2010) was further 
confirmed to not affect cell viability and was used in this study to pre-treat THP-1-
derived macrophages. The cytotoxic effect on cell viability of SB202190 MAP kinase 
inhibited-THP-1-derived macrophages (SB202190inTHP-1-derived macrophages) of 
cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) complex was 
assessed. Figure 4.8 showed the effect of cardamonin, cardamonin-Cu(II) complex 
and cardamonin-Fe(II) complex on SB202190inTHP-1-derived macrophages 
following 24 hrs treatment. Results revealed a similar trend to p38inTHP-1-derived 
macrophages and THP-1-derived macrophages where cells maintained their viability 
above 90% following cardamonin treatment on SB202190inTHP-1-derived 
macrophages. Similarly, cardamonin-Cu(II) complex was most cytotoxic towards 
SB202190inTHP-1-derived macrophages and cardamonin-Fe(II) was equally non-
cytotoxic towards SB202190inTHP-1-derived macrophages as p38inTHP-1-derived 
macrophages. 
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Figure 4.7 SB202190 p38 MAP kinase inhibitor IV. Synonym: 4-(4-
Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole. 
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Figure 4.8 Effect of cardamonin, cardamonin-Cu(II) complex and cardamonin-
Fe(II) complex on THP-1-derived macrophages cell viability in the presence of a 
MAP kinase inhibitor, SB202190.  
THP-1-derived macrophages were exposed to various concentrations (6.25, 12.5, 25, 
50 and 100 µM) of cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) 
complex in the presence of 10 µM SB202190 MAP kinase inhibitor for 24 hrs. The 
MTS assay was used to assess cell viability as described in the Materials and Methods 
section. Results were expressed as mean ± SEM from three independent experiments. 
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4.2.7 Comparative effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
on cell viability of  THP-1 monocytes, THP-1-derived macrophages, p38inTHP-1-
derived macrophages and SB202190inTHP-1-derived macrophages 
 
Building from the results obtained from Section 4.2.1, 4.2.4, 4.2.5 and 4.2.6, the 
effect on cell viability following THP-1 cell differentiation and inhibition of p38 
MAP kinase was evaluated for each compound. Figure 4.9A shows the effect of 
cardamonin (6.25, 12.5, 25, 50 and 100 µM) after 24 hrs against THP-1 monocytes, 
THP-1-derived macrophages, p38inTHP-1-derived macrophages and 
SB202190inTHP-1-derived macrophages. Results revealed a significant increase in 
cell viability at the three highest concentrations of cardamonin tested for THP-1-
derived macrophages when compared to non stimulated-THP-1 monocytes. At 25, 50 
and 100 µM cardamonin, the THP-1-derived macrophages viability increased 14%, 
19% and 17% respectively compared to THP-1 monocytes. Even though there was an 
increase in cell viability for THP-1-derived macrophages at 12.5 µM compared to 
THP-1 monocytes, this increase was insignificant. Following the inhibition of p38 
MAP kinase activity, there were no significant changes in cell viability of p38inTHP-
1-derived macrophages and SB202190inTHP-1-derived macrophages compared to 
THP-1-derived macrophages. Overall, THP-1 monocytes were more susceptible to 
cardamonin treatment compared to the macrophages. 1 µM p38 MAP kinase inhibitor 
and 10 µM SB202190 MAP kinase inhibitor were confirmed to have no affect on the 
cell viability of THP-1-macrophages. Figure 4.9B compares the effect of 
cardamonin-Cu(II) complex on THP-1 monocytes, THP-1-derived macrophages, 
p38inTHP-1-derived macrophages and SB202190inTHP-1-derived macrophages where 
results revealed a significant increase in cell viability at 25, 50 and 100 µM 
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cardamonin-Cu(II) for THP-1-derived macrophages compared to non stimulated-
THP-1 monocytes. The increase in THP-1-derived macrophages cell viability at 12.5 
µM was insignificant from the monocytes. The observed trend was very similar to 
cardamonin and the inhibition of p38 MAP kinase activity did not significantly affect 
cell viability of p38inTHP-1-derived macrophages and SB202190inTHP-1-derived 
macrophages compared to THP-1-derived macrophages when treated with 
cardamonin-Cu(II). Overall, THP-1 monocytes were more susceptible to cardamonin-
Cu(II) complex treatment compared to the macrophages. In Figure 4.9C, 
cardamonin-Fe(II) complex significantly improved cell viability by >25% and >35% 
in THP-1-derived macrophages at 50 and 100 µM respectively compared to THP-1 
monocytes. Following the inhibition of p38 MAP kinase activity, there were no 
significant changes in cell viability of the p38inTHP-1-derived macrophages and 
SB202190inTHP-1-derived macrophages compared to THP-1-derived macrophages. 
In general, THP-1 monocytes were most susceptible to all treatments compared to 
THP-1-derived macrophages, p38inTHP-1-derived macrophages and 
SB202190inTHP-1-derived macrophages. Taken together, interference from inhibitors 
of p38α and p38β on THP-1-derived macrophages did not alter cell susceptibility 
towards cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) treatments suggesting 
p38 MAP kinase was not mainly involved in THP-1-derived macrophages increased 
cell viability and resistance. 
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Figure 4.9 Comparative effects of cardamonin, cardamonin-Cu(II) complex and 
cardamonin-Fe(II) complex on cell viability of THP-1 monocytes, THP-1-derived 
macrophages and p38 MAPK-inhibited THP-1-derived macrophages.  
Cells were exposed to various concentrations (6.25, 12.5, 25, 50 and 100 µM) of 
cardamonin (A), cardamonin-Cu(II) complex (B) and cardamonin-Fe(II) complex (C) 
for 24 hrs and MTS assay was used to assess cell viability as described in the 
Materials and Methods section. Results were expressed as mean ± SEM from three 
independent experiments. *indicates significant increase (p < 0.05) from THP-1 
monocytes cell viability. 
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4.3 Discussion 
 
 Even though the role of cell adhesion as a growth regulatory mechanism has 
not been studied extensively, earlier investigations confirmed a direct relationship 
between cell spreading and DNA synthesis (Ben-Ze’ev et al. 1980, O’Neill et al. 
1986, Ingber et al. 1987). In this study, a single cell line capable of dual adherent-
suspension culture environments was used to study the role of cell adhesion in 
regulating cell death. Results clearly demonstrated that cardamonin, cardamonin-
Cu(II) and cardamonin-Fe(II) complexes were relatively more cytotoxic in THP-1 
monocytes compared to THP-1-derived macrophages, suggesting that suspension 
cells are indeed more susceptible compared to adherent cells that were more resistant. 
This occurrence is most likely due to the fact that adherent cells exhibit cell to cell 
and cell to matrix interactions, a distinct feature from suspension cells (Meredith et al. 
1993, Salge et al. 2001). Previous studies have shown that extracellular matrix (ECM) 
interaction prevented cells from undergoing apoptosis and served as a survival factor 
for mesangial cells (Sugiyama et al. 1998). Gut epithelial and ureteral epithelial cells 
have also been reported to undergo cell death when detached (Meredith et al. 1993), 
demonstrating that ECM cell adhesion is critical for cell survival and growth (Lock 
and Debnath 2008, Marastoni et al. 2008). Additionally, integrins are main receptor 
proteins cells used to bind and respond to the extracellular matrix. They are made up 
of transmembrane αβ heterodimers and responsible for mediating cell-cell attachment 
(Franceschi et al. 2015, Pan et al. 2016). It is well established that integrin-mediated 
adhesions to the extracellular matrix is vital for survival of numerous cell types and 
the activation of various integrins is needed to facilitate cells differentiating from 
suspension to adherence (Faull and Ginsberg 1995). The integrin-dependent survival 
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in epithelial and vascular endothelial cells was first described by Meredith et al. 
(1993). Cells undergo apoptosis in the absence of proper extracellular matrix contact 
and activation of specific integrins is able to prevent entry into this programmed cell 
death pathway (Meredith and Schwartz 1997, Gilmore et al. 2000). Interestingly, a 
study has found that the inhibition of fibroblast adherence to extracellular matrix did 
not actually alter certain integrin cell surface expression (Margarona et al. 1997). A 
previous study carried out to elucidate the structure and function of β5 integrins 
reported that the β5 integrins subunit involved both fibronectin and vitronectin 
adhesion, with fibronectin being the preferred ligand for K562 myeloid leukaemia 
cells (Pasqualini et al. 1993). β5 expression was also found to be absent from all 
lymphoid cell lines examined, weakly expressed on myeloid cells but expressed at 
moderate to high levels in all the adherent cells examined. Furthermore, Pasqualini et 
al. (1993) confirmed integrin β5 was highly expressed on carcinoma cell and on all 
adherent cell lines tested. Most notably, integrin β5 was absent from the B and T 
lymphoid cell lines tested and expressed weakly in some myeloid cell lines. 
  
 Additionally, a similar trend has been reported by another study carried out on 
methotrexate, a treatment of rheumatoid arthritis, comparing the uptake of 
methotrexate in suspension cells versus adherent cells (Kimura et al. 2004). The 
researchers compared the IC50 of methotrexate against 3 types of suspension cells 
(FM3A, 2B4 and THP-1) and adherent cells (NIH3T3 and V79). They found that the 
IC50 values of all three cell lines in suspension were lower compared to the two 
adherent cell lines tested. They suggested that this preferential effect of inhibition by 
methotrexate in suspension cells was mainly due to a more rapid uptake of the 
compound. The rapid uptake of compounds by suspension cells could also be due to 
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the larger surface area of suspension cells compared to adherent cells hence the 
compound is easily accumulated in suspension cells. These findings further support 
our results and provided some understanding as to why THP-1-macrophages were 
more resistant to cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) compared to 
the THP-1 monocytes. 
 
 Also, the highly motile macrophages respond to a wide range of motility and 
adhesion signals via complex signalling pathways such as the G protein-coupled 
receptors, tyrosine kinase receptors and integrin mediated signalling pathways 
(Neumeister et al. 2003). Studies found that the extracellular matrix metalloproteinase 
inducer (EMMPRIN) is up regulated in THP-1 matured macrophages (Huang et al. 
2008, Mittar et al. 2011). The up-regulation of EMMPRIN, also known as CD147, 
increased the secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 
leading to THP-1 cells enhanced invasive ability (Zhou et al. 2005). This finding is in 
accordance with Kohro et al. (2004) who previously reported a significant increase in 
MMP-9 gene following THP-1 differentiation into matured macrophages. Huang et 
al. (2008) also highlighted that during the up-regulation of EMMPRIN expression in 
THP-1 matured macrophages, the MAP kinases p38 pathway and ERK 1/2 are 
activated, but not the JNK pathway.  
 
 Overall, the MAP kinase signalling pathways play a vital role in regulating life 
and death in cancer cells and sensitivity to drug therapy as emphasised by Dhillon et 
al. (2007) and Yang et al. (2012). To investigate the role of MAP kinase signaling 
pathway on THP-1-derived macrophages in this study, the p38 MAP kinase inhibitor 
was selected as it inhibits key intermediates at various upstream/ downstream levels 
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of the MAP kinase pathway. The ATP-competitive inhibitors used in this study 
actively target the p38α and p38β receptors as well as less actively targets p38γ, p38σ, 
ERK1/2, and JNK1/2/3 receptors (Sigma-Aldrich 2017). Results revealed that the 
THP-1 cells adapted to grow in adherent macrophage-like conditions in the presence 
of p38 MAP kinase inhibitor and SB202190 MAP kinase inhibitor were equally 
resistant to treatment as THP-1-derived macrophages, suggesting the p38α and p38β 
MAP kinase pathway was not mainly responsible for the increase in cell resistance.  
 
 Interestingly, a recent study carried out by Yang et al. (2012) reported that 
curcumin, a chalcone similar to cardamonin, induced apoptotic cell death in THP-1 
cells through activation of JNK/ERK/AP1 pathways. Curcumin was found to elevate 
JNK/ERK much greater than p38 in THP-1 cells and subsequently augment 
downstream transcription factors of JNK and ERK, c-Jun and JunB. In line with the 
findings in this study, the differentiated cells dramatically reversed curcumin-induced 
cell death of THP-1 cells from 25% to 96% cell viability. This study underlines the 
significance of other MAP kinase pathways beside p38. In a separate study, a 
polyphenol, resveratrol, has been reported to inhibit EMMPRIN expression through 
the MAP kinase pathway, namely the p38 and ERK1/2 pathways in differentiated 
THP-1 cells (Huang et al. 2008). Interestingly, when we compared the chemical 
structure of cardamonin to resveratrol, there were undeniable resemblance between 
the two compounds with both compounds have a total of two benzene rings, an alkene 
group connecting the two benzene rings as well as the presence of phenolic groups 
that are almost at the same sites of the rings. These data suggest p38 MAP kinase, 
specifically p38α and p38β, may not be directly involved in THP-1-macrophages 
increased resistance towards cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
126 
 
treatment but further studies should be carried out to determine the involvement of 
other MAP kinase pathways involving JNK and ERK protein kinases. 
 
 Taken together, differentiation of leukaemic cells has been thought as an anti-
leukaemia approach for the aberrant immature blood cells. Indeed this study has 
shown that cardamonin and its two complexes became less cytotoxic following THP-
1 differentiation into THP-1-derived macrophages stimulation compared to the 
monocytes counterpart. Even though the inhibition of p38 MAP kinase did not alter 
the cell susceptibility towards cardamonin and its complexes in THP-1-derived 
macrophages, the involvement of the MAP kinase pathway particularly in human 
acute myeloid leukaemia is certain and should be further investigated. Subsequent 
work should be carried out to confirm the MAP kinase activity in THP-1 monocytes 
and THP-1-derived macrophages. Besides, various studies have highlighted the 
activation of ERK and JNK and/ or p38 protein kinases by anti-cancer compounds in 
human leukaemia cells (Chen et al. 2008, Torres et al. 2008, Chang et al. 2010, Jin et 
al. 2010). Hence, future studies should further focus on ERK and JNK activation in 
determining the molecular mechanism of cardamonin and its complexes as well as 
elucidating the different death mechanism of THP-1 cells compared to matured THP-
1 macrophages. Lastly, our data implies the novel use of cardamonin and its 
complexes as potential anti-leukemia agent that was more effective against immature 
leukaemic cells than mature cells.  
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CHAPTER 5: ELUCIDATING THE CYTOTOXIC 
MECHANISM OF ACTION INDUCED BY 
CARDAMONIN AND ITS COMPLEXES IN JURKAT T 
CELLS 
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5.1 Introduction   
 
As previously reported in Chapter 3, cardamonin-Cu(II) complex and cardamonin-
Fe(II) complex were the two most cytotoxic cardamonin derivatives against A549 
lung and HK1 nasopharyngeal human carcinoma cell line. Subsequent cytotoxicity 
studies carried out using these compounds on the human leukemia T cells, Jurkat T 
cells, revealed that these two complexes were again most cytotoxic with lowest IC50 
values reported. Hence, in this study, Jurkat T cells were chosen as the cell culture 
model to explore the cytotoxicity of cardamonin and its metal complexes and the 
underlying mechanism of action leading to Jurkat T cell death. As previous studies 
showed that cardamonin activates cell death mainly through apoptosis (Table 1.3), we 
determine the involvement in apoptotic cell death by introducing a caspase inhibitor 
since one of the characteristic features of apoptosis is caspase activation. This study 
further concentrates on elucidating whether mitochondria dysfunction, PS 
externalisation and caspase cascades are involved in Jurkat T cell death that 
potentially leads to apoptosis. To our best knowledge, this study is the first to 
demonstrate the induction of apoptosis by cardamonin and its two novel metal 
complexes in Jurkat T cells. 
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5.2 Results 
5.2.1 Effects of cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) 
complex on cell viability in the presence of a caspase inhibitor, Z-VAD-FMK, in 
Jurkat T cells  
 
To examine whether cardamonin-, cardamonin-Cu(II)- and cardamonin-Fe(II)-
induced cell death in Jurkat T cells is via apoptosis, the effects of Z-VAD-FMK, a 
cell-permeable caspase inhibitor was investigated. As shown in Figure 5.1, Z-VAD-
FMK was able to block cell death induced by cardamonin and its complexes. The cell 
viability of Jurkat T cells treated with 50 and 100 µM of Z-VAD-FMK were 
significantly higher compared to cells treated with cardamonin and its complexes 
alone. The increased Z-VAD-FMK concentration from 50 to 100 µM also revealed an 
increased in cell viability further suggesting that caspases are involved in all three 
compounds-induced apoptotic cell death.  
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Figure 5.1 Effects of cardamonin and its complexes (IC50 values) on cell viability 
in Jurkat leukemia T cells in the absence or presence of caspase inhibitor, Z-
VAD-FMK (50 or 100 µM).  
A cathepsin B inhibitor, Z-FA-CMK, which is known to induce apoptosis at low 
concentrations in Jurkat leukemia T cells, was used as the positive control (8 µM). 
Control cells represent untreated cells. Cells were treated and incubated for 24 hrs 
then assessed for cell viability using the MTS assay. Data represents the mean ± SEM  
(n = 3 replicates) and representative of three independent experiments. *indicates 
significantly different (p < 0.05) from treated cells in the absence of Z-VAD-FMK. 
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5.2.2 Morphological changes induced by cardamonin, cardamonin-Cu(II) complex 
and cardamonin-Fe(II) complex on Jurkat T cells 
 
Hallmarks of apoptotic cell death can be detected in the changes of nuclear 
morphology such as nuclear DNA condensation, cell shrinkage, plasma membrane 
blebbing and nuclear fragmentation into apoptotic bodies. Jurkat T cells were exposed 
for 24 hrs to cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) using the IC50 
values. Figure 5.2A-E illustrated the cell morphology using contrast phase 
microscopy. Cells were fixed and stained with the DNA Hoechst dye after treatment 
and viewed using fluorescence microscopy as shown in Figure 5.2F-J. As 
demonstrated in Figure 5.2F, normal control Jurkat T cells were lightly stained with 
the DNA dye and exhibited normal nuclear morphology. However, apoptotic 
characteristics were presented in cells treated with cardamonin and both its complexes 
such as shrinkage of cells, chromatic condensation, and cell membrane blebbing 
(Figure 5.2G-J).  
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Figure 5.2 Effects of cardamonin and its complexes (IC50 values) on 
morphological and nuclear DNA changes in Jurkat leukemia T cells.  
Cells were treated and incubated for 24 hrs then fixed with 4% paraformaldehyde and 
stained with Hoechst 33358 dye. Cell morphological changes typical of apoptosis 
were observed using the Olympus fluorescence microscope. The optical microscopic 
images of control cells (A), cardamonin-treated cells (B), cardamonin-Cu(II)-treated 
cells (C), cardamonin-Fe(II)-treated cells (D), and STS-treated cells (E). Nuclear 
DNA morphology of control cells (F), cardamonin-treated cells (G), cardamonin-
Cu(II)-treated cells (H), cardamonin-Fe(II)-treated cells (I), and STS-treated cells (J) 
by Hoechst 33358 staining. Original magnification X400. White arrows indicate 
normal cell morphology, yellow arrows indicate cell shrinkage, red arrows indicate 
DNA/ chromatin condensation, nuclear fragmentation, plasma membrane blebbing 
and green arrows indicate formation of apoptotic bodies. 
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5.2.3 Analysis of phosphatidylserine externalisation during apoptosis using FITC-
conjugated annexin in Jurkat T cells 
 
For further assessment of apoptosis, the exposure of PS on the cell surface was 
examined using Annexin-V/PI double staining and determined by flow cytometer. 
Cell were treated with IC50 values of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) for 24 hrs prior to Annexin-V/PI assessment. STS, a non-selective 
protein kinase inhibitor that is known to induce apoptosis, was used as the positive 
control where cells were treated with 1 µM STS for 4 hrs. Figure 5.3A represents the 
dot plots of control cells, STS, cardamonin-treated cells, cardamonin-Cu(II)-treated 
cells, and cardamonin-Fe(II)-treated cells. As illustrated in Figure 5.3B, the viable 
cells of all treated cells were significantly lower when compared to control cells, 
which has the most viable cells. Conversely, all treated cells were significantly higher 
in the number of early apoptotic cells when compared to number of control cells. In 
parallel with this, there was an increased in late apoptotic cells where cardamonin- 
and cardamonin-Fe(II)-treated cells were significantly higher than the control cells. 
On the contrary, the necrotic cells population seemed rather constant in these 
conditions.  
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Figure 5.3 Flow cytometry examination of apoptosis, necrosis and cell viability – 
the Annexin V-FITC/PI assay.  
Representative dot plots of control cells, STS, cardamonin-treated cells, cardamonin-
Cu(II)-treated cells, and cardamonin-Fe(II)-treated cells (A). LL: viable cells, LR: 
early apoptotic cells, UR: late apoptotic cells, and UL: necrotic cells. The percentage 
of viable, early apoptotic, late apoptotic, and necrotic cells (B). Data represents the 
mean ± SEM  (n = 3 replicates) and representative of three independent experiments. 
*indicates significantly different (p < 0.05) from control with media alone.  
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5.2.4 Western blot analysis of caspase activation by cardamonin, cardamonin-Cu(II) 
complex and cardamonin-Fe(II) complex in Jurkat T cells 
 
Since Z-VAD-FMK alleviates cell death induced by cardamonin and its complexes, 
we examined the activation of caspases in Jurkat T cells exposed to cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II) as well as STS (positive control). Results 
in Figure 5.4 reveal all the caspases, caspase-3, -8 and -9 remained intact in the 
control untreated cells. On the contrary, treatment with cardamonin, cardamonin-
Cu(II) and cardamonin-Fe(II) resulted in the processing of caspase-3 and -9 but not -8 
in Jurkat T cells. Pro-forms of caspase-3 and -9 were cleaved into their p17/19/20 and 
p35/37 fragments, respectively. PARP-1, a caspase-3 substrate, was also cleaved from 
p116 to the signature p85 fragment. These results further confirmed that cell death 
induced by cardamonin and its complexes is via the apoptotic pathway. In the 
presence of the caspase inhibitor, Z-VAD-FMK, the processing of all the caspases 
were inhibited and the cleavage of PARP-1 was completely suppressed.  
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Figure 5.4 Effect of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on 
the activation of caspase-3, -8 and -9 and the cleavage of PARP-1 in Jurkat T 
cells.  
Cells were treated in the presence or absence of caspase inhibitor, Z-VAD-FMK (100 
µM). Cells were treated with 1 µM STS for 4 hrs as a positive control. SDS-PAGE 
and western blotting techniques were used to analyse the activation of caspases and 
the cleavage of PARP-1 as described in Materials and Methods section. Results are 
representative of at least three separate experiments. *indicates non-specific bands on 
blots. 
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5.2.5 Effects of cardamonin, cardamonin-Cu(II) complex and cardamonin-Fe(II) 
complex on MMP in Jurkat T cells 
 
Collapse of the MMP on the cell surface membrane of cells undergoing apoptosis is 
one of the earliest changes that precedes the externalisation of PS. As witnessed in 
Figure 5.5, exposure to cardamonin and both its complexes for 24 hrs significantly 
decreased the percentage of positively stained TMRE cells, contrary to the untreated 
control cells where the MMP remained intact. Overall, this study shows cardamonin 
induces apoptosis in a similar way to the known apoptotic inducer, STS. 
 
 
Figure 5.5 Effects of cardamonin and its complexes on the MMP in Jurkat T 
cells.  
After 24 hrs treatment with IC50 values of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II), the MMP was measured by the percentage of fluorescence 
intensity compared to the control using the TMRE assay. Cells were treated with 1 
µM STS for 4 hrs as a positive control. Data represents the mean ± SEM  (n = 3 
replicates) and representative of three independent experiments. *indicates 
significantly different (p < 0.05) from control with media alone. 
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5.3 Discussion 
 
To date, many natural products have been screened for their anti-cancer potential via 
different experimental models. In the present study, cardamonin was complexed with 
copper and iron metal ions and assessed for the cytotoxicity profile. Transition-metal 
complexes are increasingly being considered as promising anti-cancer drugs (Deegan 
et al. 2006) as metal ions are vital for many biological processes and are constantly 
available in the human body (Tang and Liang 2013). Results in Chapter 3 revealed 
both cardamonin-Cu(II) and cardamonin-Fe(II) complexes showed an increased 
cytotoxicity as the concentration increased. Compared to the original parent 
compound, cardamonin, addition of copper and iron to cardamonin increased the 
cytotoxic efficacy of the compounds by more than fourfold and twofold, respectively.  
 
 To examine the mode of action of cardamonin and its complexes, we first used 
Z-VAD-FMK to block the activation of caspases and their activity in Jurkat T cells. 
The synthetic broad-spectrum caspase inhibitor, Z-VAD-FMK, is used extensively in 
elucidating the role of caspases during apoptosis. The presence of Z-VAD-FMK 
markedly inhibited cell death induced by cardamonin and its complexes. When 
concentration of Z-VAD-FMK was increased from 50 to 100 µM, the cell viability 
was almost completely restored. These results suggest that cell death induced by 
cardamonin and its complexes is caspase-dependent. As activation of caspase is 
known to promote apoptosis, we next observed the cell nuclear morphology changes 
after treatment using the fluorescent DNA-binding agent, Hoechst stain. The 
morphological changes revealed distinct hallmarks of apoptosis and caspases have 
been implicated to play a major role in this process. To examine this in greater detail, 
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cells were observed under both contrast phase and fluorescent microscopy looking at 
the cell on the whole and staining the DNA, respectively. It was confirmed that cells 
treated with cardamonin and its complexes displayed chromatin condensation, cell 
shrinkage and apoptotic bodies which are all the distinct features of cells undergoing 
apoptosis. Although nuclear staining using Hoechst stain is used widely to determine 
cell death, this technique does not provide quantification nor distinguish cells in early 
apoptosis state from those in late apoptosis state. For better characterisation of cell 
death, after cell staining, cells were subjected to flow cytometry analysis using 
annexin V.  
 
 In order to support the hypothesis that cardamonin and its complexes-induced 
cell death was responsible for the induction of apoptotic cell death, Jurkat cells were 
stained with Annexin-V FITC and propidium iodide (PI). Annexin V is a calcium 
dependent phospholipid binding protein that has high binding affinity to PS. This high 
binding affinity of Annexin-V is utilised during translocation of PS from the inner to 
outer leaflet of the plasma membrane that occurs during apoptosis (Widau et al. 
2014). PI on the contrary has high affinity towards nucleic acids and selectively enters 
late apoptotic or necrotic cells. The number of stained cells was estimated via flow 
cytometry where these results indicated that cardamonin and its complexes induced 
significant cell death through apoptosis. The dual staining of Annexin-V and PI made 
it possible to identify early apoptotic, later apoptotic, live and dead cells. In current 
observations, the majority of cells, ranging from 65% – 75%, exposed to cardamonin 
and its complexes for 24 hrs were undergoing early apoptosis with less than 25% of 
normal cells present. These results taken together with the microscopic findings 
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provided further supportive evidence that treatment with cardamonin and its two 
complexes induced apoptotic cell death.  
 As mentioned earlier, the key regulator proteases of apoptotic pathways are 
caspases which, when activated provides confirmatory evidence of apoptotic events. 
In this study, cardamonin and its complexes induced caspase-3 and -9 activation but 
not caspase-8 following 24 hrs treatment in Jurkat T cells. To further confirm the role 
of caspases, activation of PARP-1 was assessed, a well-known substrate of caspase-3. 
Indeed, Jurkat T cells treated with cardamonin, cardamonin-Cu(II) and cardamonin-
Fe(II) complex induced cleavage of PARP-1 (116 kDa) resulting in the accumulation 
of the 85 kDa cleavage product. Modification of this protein occurs in response to 
DNA damage (Bouchard et al. 2003). Furthermore, PARP-1 has been implicated in 
numerous vital cellular processes such as DNA repair, DNA replication and 
transcription, genome stability and apoptosis (Bouchard et al. 2003). In the presence 
of the caspase inhibitor, Z-VAD-FMK, the processing of caspase-3, -9 and the 
cleavage of PARP-1 mediated by cardamonin and its complexes was completely 
abrogated. These results demonstrated that cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) complex-induced cell death is indeed a caspase-dependent process. 
These findings suggested that these compounds activated the intrinsic apoptotic 
pathway, also known as the mitochondrial apoptosis pathway.  
 
 It has been well documented that apoptosis is initiated by two signalling 
pathways, extrinsic and intrinsic pathway (Green 2000). The extrinsic pathway 
involves interaction of cell surface receptors like tumour necrosis factor (TNF), Fas 
and TNF-related apoptosis-inducing ligand (TRAIL), which in turn activates the 
downstream initiator caspases, caspase-8. Activation of caspase-8 can lead to direct 
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activation and cleavage of downstream effector caspases including caspase-3 (Parrish 
et al. 2013). In certain cell lines, this pathway is all that is needed to cause cell death. 
On the contrary, in other cell types, caspase-8 must also engage the mitochondria and 
enter the intrinsic pathway to undergo apoptosis (Li et al. 1998, Luo et al. 1998). 
Principally, the initiator caspase-8 of the extrinsic pathway is initiated at the plasma 
membrane. FasL receptor interacts with Fas transmembrane receptor leading to 
receptor oligomerisation. The Fas receptor death domain (DD) allows the recruitment 
of FADD adaptor protein from the cell cytoplasm via its DD. Interaction between the 
death effector domain (DED) on FADD initiate the recruitment of caspase-8 to the 
complex. Active initiator caspase-8 can directly activate effector caspase-3 or in some 
cases the initiator caspase facilitates mitochondrial cytochrome c release BID 
cleavage, initiating the intrinsic mitochondrial pathway. Intrinsic apoptosis depends 
on the factors released from mitochondria. The initiator caspase-9 directly activates 
the mitochondria-dependent intrinsic pathway. At the mitochondria, pro-apoptotic 
(BAX and BAK) and anti-apoptotic BCL-2 (BCL-2 and BCL-xL) family members 
facilitate and inhibit cytochrome c release from the mitochondrial intermembrane 
space respectively (Parrish et al. 2013). Cytochrome c interacts with apoptotic 
protease-activating factor-1, Apaf-1, and undergoes oligomerisation into apoptosome, 
a heptameric structure, once it translocates into the cytosol (Shiozaki et al. 2002). The 
apoptosome activates the recruited initiator caspase-9, which then directly cleaves and 
activates effector caspase-3. 
 
 Coupled with the results observed in Figure 5.1 and Figure 5.4, the presence 
of the caspase inhibitor Z-VAD-FMK has alleviated cell death in a dose dependent 
manner and the activation of initiator caspase-9 and executioner caspase-3 were 
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inhibited. The pathway described above further confirms that cell death in Jurkat T 
cells mediated by cardamonin and its two complexes are caspase-dependent and 
involved the intrinsic mitochondrial pathway. Although in this study caspase-8 was 
not activated following 24 hrs treatment with cardamonin and its two complexes, a 
recent study have shown activation of this initiator caspase by cardamonin in human 
colon cancer cells (Yadav et al. 2012). Even though the study is in conflict with the 
findings in this study, an interesting observation was seen in another study measuring 
caspase-8 luminescent in the cell-based assay that demonstrated the caspase-8 activity 
in Jurkat T cells was optimum 3 hrs following drug treatment (Farfan et al. 2004). As 
caspase-8 has the ability to indirectly activate the intrinsic mitochondrial pathway (Li 
et al. 1998, Parrish et al. 2013), a quantitative western blot study at different time 
points before 24 hrs can be carried out to assess the possible activation of caspase-8 in 
this study.  
 
 Several studies have reported the loss of MMP induced by chalcone 
derivatives i.e. loss of MMP in (1) cervical cancer cells induced by Flavokawain B 
(Lin et al. 2012); (2) colon cancer cells by Ch1 and Ch2 chalcone derivatives (Kello 
et al. 2016); and (3) nasopharyngeal cancer cell by curcumin (Kuo et al. 2011), where 
caspase-3-dependent apoptotic death took place. It has been well established that the 
loss of MMP occurs during early stages of apoptosis where caspase activation further 
induces permeabilisation of the mitochondrial membrane. Depolarisation of 
mitochondria plays a vital role in triggering cell death and activation of apoptosis. 
Cell death is triggered through the release of apoptotic proteins to the cytoplasm from 
the disturbed and disrupted mitochondrial membrane (Ferreira et al. 2012). The MMP 
results obtained in this study confirmed that cardamonin, cardamonin-Cu(II) and 
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cardamonin-Fe(II) induced mitochondrial dysfunction and decreased in MMP. Loss 
of MMP is an initial requirement for cellular apoptosis. This finding further supports 
Annexin-V-FITC binding results and also correlates to the morphological studies 
which all displayed the hallmarks of apoptotic cell death in Jurkat T cells induced by 
cardamonin and its two complexes.  
 
 Taken together, induction of apoptotic cell death can be regarded as a 
therapeutic function that is aimed to eliminate damaged cells. Hence, the goal for 
therapy against neoplastic cells now aims to trigger apoptosis, programmed cell death. 
In this chapter, it was shown that cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes have higher cytotoxic activity than cardamonin itself. Both complexes and 
cardamonin induced cellular morphological changes that were typical of apoptosis. 
The exposure of PS and decline in the MMP indicated that both these complexes are 
promising anti-cancer agents as inducers of apoptotic cell death. Cardamonin-Cu(II) 
and cardamonin-Fe(II)-induced apoptosis in Jurkat T cells are through caspase-
dependent mitochondrial pathway, similar to cardamonin. Based on the data obtained 
in this study thus far, the hypothesis that DNA damage in cells could be highly 
preferentially due to oxidative species produced by transition metal ions will be 
further evaluated in the following chapter to better elucidate the mechanism of action 
of these novel compounds.   
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CHAPTER 6: OXIDATIVE MECHANISMS OF 
CARDAMONIN, CARDAMONIN-Cu(II) AND 
CARDAMONIN-Fe(II) COMPLEXES IN JURKAT T 
CELLS 
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6.1 Introduction   
 
In previous chapter, the mechanism of action of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) complexes were investigated in Jurkat T cells. The results 
illustrated that both complexes and cardamonin induced cellular morphological 
changes that are typical of apoptosis, exposing PS and the loss of MMP. All three 
compounds induced apoptosis in Jurkat T cells through caspase-dependent 
mitochondrial pathway, activating caspase-3, caspase-9 and PARP-1. In this study, 
cardamonin was complexed with metal ions, and cytotoxicity of cardamonin-Cu(II) 
and cardamonin-Fe(II) in Jurkat T cells was examined. As previous studies have 
reported the ability of metals to induce cytotoxicity through oxidative stress (Aruoma 
et al. 1991, Shi et al. 2004, Valko et al. 2005, Fahmy and Cormier 2009), this chapter 
explored possibilities of cardamonin and its complexes eliciting oxidative stress or 
anti-oxidant pathway predisposing the Jurkat T cells to apoptosis. Metal-induced 
cytotoxicity has been widely recognised with its ability to generate reactive oxygen 
and nitrogen species as well as depleting GSH levels in cells (Ercal et al. 2001, Shi et 
al. 2004, Valko et al. 2005). Metal has the ability to bind directly to thiols or involve 
in the formation of H2O2. On the other hand, anti-oxidants have been shown to 
provide protection against metal-mediated free radical attacks (Curtin et al. 2002). 
Examples of commonly used anti-oxidants include NAC, Trolox, L-cysteine and GSH 
that have been shown to protect cells and reverse cell death (Buttke and Sandstrom 
1994, Poliandri et al. 2003, Hadzic et al. 2005, Park et al. 2007, Marreilha et al. 2008, 
Sun 2010, Maheshwari et al. 2011, Saxena et al. 2014). Accordingly, GSH is the most 
abundant non-protein thiol that plays a vital role in regulating apoptosis and 
functioning as a ROS scavenging enzyme substrate (Circu and Aw 2008). In addition, 
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the amino-thiol, NAC, is a commonly used synthetic research tool to investigate the 
role of oxidative stress in the induction of apoptosis due to its ability to act as a 
precursor of GSH and intracellular cysteine (Zafarullah et al. 2003). Although NAC is 
widely used to demonstrate the involvement of oxidative stress in treatment-induced 
apoptosis, Sun (2010) suggested the use of multiple anti-oxidants including both 
thiols and non-thiols to confirm the implications of oxidative stress and apoptosis. 
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6.2 Results 
6.2.1 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
cell viability in the presence of NAC in Jurkat T cells 
 
NAC, a thiol known to be a ROS scavenger and a precursor of GSH synthesis, was 
added to Jurkat T cells to determine if NAC could alleviate the cytotoxicity effects of 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II)-mediated cell death. As 
illustrated in Figure 6.1, NAC was able to significantly block cardamonin and 
cardamonin-Fe(II)-induced Jurkat T cell death by >40% compared to treatment in the 
absence of NAC following 24 hrs treatment. On the contrary, NAC was not able to 
restore cell death mediated by cardamonin-Cu(II) complex. The presence of NAC 
alone at 1 mM has no affect on Jurkat T cell viability compared to the control as 
depicted below. Since NAC was able to block cell death mediated by cardamonin and 
cardamonin-Fe(II) complex in Jurkat T cells, these results suggest that oxidative 
stress is involved in the cytotoxic effects of these two compounds. These results and 
initial findings further warrant the analysis of intracellular ROS and GSH levels 
following cardamonin and its complexes treatment in Jurkat T cells. 
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Figure 6.1 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on cell viability in the presence or absence of NAC in Jurkat T cells. 
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of NAC for 24 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. *indicates significant decrease (p 
< 0.05) from control; *above bracket indicates significant different (p < 0.05) from 
the respective compound treatment alone. 
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6.2.2 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
intracellular ROS levels in Jurkat T cells 
 
The potential of cardamonin and cardamonin-Fe(II) complex to induce oxidative 
stress as shown in Figure 6.1 was further assessed by measuring the intracellular 
ROS levels. Results in Figure 6.2 revealed that all three compounds, cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II) complexes significantly induced the 
intracellular production of ROS. Cardamonin-Fe(II) and cardamonin induced 
intracellular ROS levels by 1.36 and 0.98-fold respectively compared to control in 
Jurkat T cells. Surprisingly, cardamonin-Cu(II) complex was shown to significantly 
increase intracellular ROS by 0.80-fold compared to control despite NAC having no 
effect on cell viability of cardamonin-Cu(II)-induced cell death. Since NAC also acts 
as a precursor of GSH synthesis besides scavenging ROS, we next examine the 
effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
intracellular GSH levels. 
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Figure 6.2 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on intracellular ROS levels in Jurkat T cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes for 24 hrs and the intracellular ROS levels were measured using the DHE 
probe as outlined in the Materials and Methods section. Results are means ± SEM of 
three independent experiments. *indicates significant increase (p < 0.05) from control. 
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6.2.3 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
intracellular GSH levels in Jurkat T cells  
 
As all three compounds were shown to increase intracellular ROS levels in Jurkat T 
cells, the intracellular GSH levels of Jurkat T cells were further assessed following 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes treatment. The 
GSH levels were measured based on 5x105 cells per treatment to ensure the GSH 
levels determined were representative of the intracellular GSH and not due to the 
decreased cell number following treatment. As illustrated in Figure 6.3, both 
cardamonin and cardamonin-Fe(II) significantly reduced intracellular GSH levels in 
Jurkat T cells by 43.73% and 39.21% respectively. Conversely, a slight decrease of 
9.79% in intracellular GSH levels induced by cardamonin-Cu(II) was not significantly 
different from the control. These findings support the results observed in Figure 6.1 
suggesting that cardamonin and cardamonin-Fe(II) complex-induced cell death is 
dependent on the intracellular GSH levels. To confirm these findings, low molecular 
weight thiols were added to Jurkat T cells in the presence of cardamonin and its 
complexes and assessed for the effects on cell viability as shown in the following 
study.  
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Figure 6.3 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on intracellular GSH levels in Jurkat T cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes for 24 hrs and the intracellular GSH levels were measured using the 
fluorescent dye MCB as outlined in the Materials and Methods section. Results are 
means ± SEM of three independent experiments. *indicates significant decrease (p < 
0.05) from control. 
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6.2.4 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
cell viability in the presence of L-cysteine in Jurkat T cells 
 
L-cysteine, a low molecular weight thiol required for GSH synthesis (Monick et al. 
2003, Hadzic et al. 2005) was added to Jurkat T cells to determine if L-cysteine could 
alleviate the cytotoxic effects of cardamonin, cardamonin-Cu(II) and cardamonin-
Fe(II)-mediated cell death. As de-acetylation of NAC is known to increase L-cysteine 
levels, is it possible that introduction of L-cysteine would similarly recover cell death 
as observed in Figure 6.1 in the presence of NAC. As shown in Figure 6.4, L-
cysteine was indeed able to significantly increase cell viability of cardamonin and 
cardamonin-Fe(II)-induced Jurkat cell death by 38.92% and 47.46% respectively 
compared to treatment in the absence of L-cysteine. In contrast, L-cysteine was not 
able to recover cell death mediated by cardamonin-Cu(II) complex suggesting that 
cardamonin-Cu(II)-induced cell death was not intracellular GSH levels dependent. 
The presence of L-cysteine alone at 5 mM was confirmed to not affect Jurkat T cell 
viability compared to the control as depicted below. Since L-cysteine was able to 
recover the cell death of Jurkat T cells mediated by cardamonin and cardamonin-
Fe(II) complex, these results suggest that depletion of GSH levels are involved in the 
cytotoxic effects of these compounds that led to cell death. To support this theory, the 
following study assessed the effects of D-cysteine, a thiol that cannot be metabolised 
to GSH (Jones et al. 1995), on Jurkat T cells viability. 
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Figure 6.4 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on cell viability in the presence or absence of L-cysteine in Jurkat T 
cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of L-cysteine for 24 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. *indicates significant decrease (p 
< 0.05) from control; *above bracket indicates significant different (p < 0.05) from 
the respective compound treatment alone. 
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6.2.5 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
cell viability in the presence of D-cysteine in Jurkat T cells 
 
Since the cell death mediated by cardamonin and cardamonin-Fe(II) were 
significantly recovered by NAC (Figure. 6.1) and L-cysteine (Figure. 6.4), we 
examine whether another low molecular weight thiol, D-cysteine, which cannot be 
metabolised into GSH (Jones et al. 1995, Rajah and Chow 2014) had any effects on 
cell viability of treated Jurkat T cells. Results in Figure 6.5 revealed the presence of 
D-cysteine had little effect on the cell viability of cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II)-treated Jurkat T cells following 24 hrs treatment. The presence of 
D-cysteine alone at 5 mM was found to have no effect on Jurkat T cell viability 
compared to the control as depicted below. Taken together, these results suggest that 
the cytotoxic effects of cardamonin and cardamonin-Fe(II) were due to oxidative 
stress via GSH depletion.  
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Figure 6.5 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on cell viability in the presence or absence of D-cysteine in Jurkat T 
cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of D-cysteine for 24 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. *indicates significant decrease (p 
< 0.05) from control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
Control D-cysteine Cardamonin Cardamonin-
Cu(II) 
Cardamonin-
Fe(II) 
C
e
ll
 V
ia
b
il
it
y
 (
%
) 
D-cysteine Present D-cysteine Absent 
* * *
158 
 
6.2.6 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
cell viability in the presence of GSH in Jurkat T cells  
 
Since previous results suggested that GSH played an important role in the cardamonin 
and cardamonin-Fe(II)-mediated cell death, the effect of exogenously added GSH on 
treated Jurkat T cells were assessed next. As shown in Figure 6.6, in the presence of 
exogenous GSH, cardamonin and cardamonin-Fe(II)-treated Jurkat T cells’ viability 
were significantly restored by 46.89% and 52.68% respectively compared to 
treatment alone in the absence of exogenous GSH. On the contrary, similar to NAC 
(Figure. 6.1) and L-cysteine (Figure. 6.4), the presence of exogenous GSH was not 
able to restore cell death mediated by cardamonin-Cu(II) complex. These data 
strongly suggest that cell death mediated by cardamonin-Cu(II) was not associated 
with the intracellular GSH levels of Jurkat T cells. The presence of exogenous GSH 
alone at 5 mM was confirmed to not affect Jurkat T cell viability compared to the 
control as depicted below. As cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes were shown to increase intracellular ROS levels (Figure. 6.2), we next 
examine the effects of a free radical scavenger, Trolox, on the cell viability of treated 
Jurkat T cells.  
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Figure 6.6 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on cell viability in the presence or absence of GSH in Jurkat T cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of GSH for 24 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. *indicates significant decrease (p 
< 0.05) from control; *above bracket indicates significant different (p < 0.05) from 
the respective compound treatment alone. 
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6.2.7 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
cell viability in the presence of Trolox in Jurkat T cells 
 
In an effort to determine if the intracellular ROS levels had an effect on the cell 
viability of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes-treated 
Jurkat T cells, Trolox, a water soluble derivative of Vitamin E, was added to remove 
generated intracellular ROS (Forrest et al. 1994, Castro et al. 2006). As illustrated in 
Figure 6.7, Trolox was indeed able to significantly increase cell viability of 
cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II)-induced Jurkat cell death by 
34.86%, 45.24% and 32.19% respectively compared to treatment in the absence of 
Trolox. The presence of Trolox alone at 1 mM was confirmed to not affect Jurkat T 
cell viability compared to the control as depicted below. Taken together, these results 
indicate that besides depleting GSH in Jurkat T cells, cardamonin and cardamonin-
Fe(II) complex also induced oxidative stress through generation of ROS leading to 
cell death. Cardamonin-Cu(II) complex on the other hand mediated oxidative stress in 
Jurkat T cell death via the generation of ROS but did not alter the levels of GSH in 
the treated cells.  
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Figure 6.7 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on cell viability in the presence or absence of Trolox in Jurkat T cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of Trolox for 24 hrs and cell viability was 
assessed via the MTS assay as outlined in the Materials and Methods section. Results 
are means ± SEM of three independent experiments. *indicates significant decrease (p 
< 0.05) from control; *above bracket indicates significant different (p < 0.05) from 
the respective compound treatment alone. 
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6.2.8 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
intracellular ROS levels in the presence of Z-VAD-FMK in Jurkat T cells 
 
As the caspase inhibitor, Z-VAD-FMK, has been shown in Figure 5.1 to recover cell 
viability of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II)-treated Jurkat T 
cells, we examined whether oxidative stress is alleviated by measuring the 
intracellular ROS levels of cells in the presence of Z-VAD-FMK. As demonstrated in 
Figure 6.8, in the presence of the pan caspase inhibitor, the intracellular ROS levels 
dropped significantly compared to the respective treatment alone in Jurkat T cells. 
The intracellular ROS levels of cardamonin, cardamonin-Cu(II) and cardamonin-
Fe(II) decreased by approximately half in the presence of Z-VAD-FMK. The 
presence of Z-VAD-FMK alone at 100 µM has no effect on Jurkat T cell intracellular 
ROS levels compared to the control as depicted below. Taken together, these data 
confirmed that the caspase-dependent apoptotic cell death was mediated by oxidative 
stress specifically by induction of ROS by cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II). We next examined whether intracellular GSH levels were altered 
in treated Jurkat T cells in the presence of Z-VAD-FMK under similar conditions. 
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Figure 6.8 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on intracellular ROS levels in the presence or absence of Z-VAD-
FMK in Jurkat T cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of Z-VAD-FMK for 24 hrs and the intracellular 
ROS levels were measured using the DHE probe as outlined in the Materials and 
Methods section. Results are means ± SEM of three independent experiments. 
*indicates significant increase (p < 0.05) from control; *above bracket indicates 
significant different (p < 0.05) from the respective compound treatment alone. 
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6.2.9 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) complexes on 
intracellular GSH levels in the presence of Z-VAD-FMK in Jurkat T cells 
 
Since the depletion of GSH has been reported to be critical for apoptotic enzymes 
activation and an early hallmark observed in apoptosis (Franco et al. 2007, Franco and 
Cidlowski 2009), we examine if Z-VAD-FMK in treated Jurkat T cells were able to 
recover the intracellular GSH levels. As seen in Figure 6.9, Z-VAD-FMK had little 
effect on the GSH levels in cardamonin-Cu(II)-treated Jurkat T cells compared to the 
respective treatment alone. This finding corresponded to the results illustrated in 
Figure 6.3 where cardamonin-Cu(II) had no effect on intracellular GSH levels further 
confirming the apoptotic cell death induced by the compound was not associated with 
the GSH levels. However, in the presence of Z-VAD-FMK, the cardamonin and 
cardamonin-Fe(II)-treated cells exhibited significant increase in intracellular GSH 
levels compared to cells with treatment alone. Collectively, these results confirmed 
that the caspase-dependent apoptotic cell death induced by cardamonin and 
cardamonin-Fe(II) also mediate oxidative stress via depletion of intracellular GSH 
levels. 
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Figure 6.9 Effects of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
complexes on intracellular GSH levels in the presence or absence of Z-VAD-
FMK in Jurkat T cells.  
Jurkat T cells were treated with cardamonin, cardamonin-Cu(II) or cardamonin-Fe(II) 
complexes in the presence or absence of Z-VAD-FMK for 24 hrs and the intracellular 
GSH levels were measured using the fluorescent dye MCB as outlined in the 
Materials and Methods section. Results are means ± SEM of three independent 
experiments. *indicates significant decrease (p < 0.05) from control; *above bracket 
indicates significant different (p < 0.05) from the respective compound treatment 
alone. 
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6.3 Discussion 
 
In the previous chapter, cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) have 
been shown to induce apoptotic cell death in Jurkat T cells. Accumulating evidences 
suggest that cardamonin is involved in oxidative stress (Mohamad et al. 2004, Li et al. 
2008, Aderogba et al. 2012) with various studies reporting cardamonin having anti-
oxidant (Ahmad et al. 2006, Simirgiotis et al. 2008) as well as a pro-oxidant (Yadav 
et al. 2012) properties. Our results demonstrated that cardamonin and both its 
complexes, cardamonin-Cu(II) and cardamonin-Fe(II), induced Jurkat T cell death 
that was mediated by oxidative stress. Specifically, cardamonin and cardamonin-
Fe(II) treatment led to depletion of intracellular GSH levels and increase in 
intracellular ROS. The cytotoxic action of cardamonin and cardamonin-Fe(II) were 
readily abolished by low molecular weight thiols added exogenously including NAC, 
L-cysteine and GSH. These findings suggested GSH as the rate-limiting thiol required 
for Jurkat T cell viability since NAC and L-cysteine are both precursors of GSH 
biosynthesis. This proposed theory was further corroborated when studies revealed 
that D-cysteine, the low molecular weight thiol that cannot be metabolised to GSH, 
was unable to restore Jurkat T cell viability in the presence of cardamonin and 
cardamonin-Fe(II) complex. As the previous chapter has shown that 100 µM Z-VAD-
FMK was able to restore cell death of Jurkat T cells in the presence of cardamonin 
and cardamonin-Fe(II), the ability of Z-VAD-FMK to alter intracellular GSH and 
ROS levels further suggest that oxidative stress potentially mediated the apoptotic cell 
death of cardamonin and cardamonin-Fe(II)-treated Jurkat T cells. These findings 
corresponded with multiple studies reporting the importance of GSH as a regulator for 
T cells suggesting a direct relationship between T cells viability and intracellular GSH 
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availability (Zmuda and Friedenson 1983, Hamilos and Wedner 1985, Gmünder and 
Dröge 1991, Kohno et al. 1996, Iwata et al. 1997, Chang et al. 2002). Studies have 
also shown the depletion of intracellular GSH leads to accumulation of high ROS 
levels (Zucker et al. 1997, Armstrong et al. 2002). As previous studies have reported 
the ability of peptidyl methylketones to alter the intracellular GSH levels (Angliker et 
al. 1987, Rajah and Chow 2014), we confirmed in this study that Z-VAD-FMK did 
not have an effect on cell viability, intracellular GSH and ROS levels at the tested 
concentration of 100 µM in Jurkat T cells. 
 
 Interestingly, in this chapter, we first observed a notable difference in the 
mechanism of action between the complex cardamonin-Cu(II) and the parent 
compound cardamonin. Studies carried out in previous chapters have demonstrated 
the biological activity of cardamonin-Cu(II) to be similar to the parent compound. 
However, in determining the oxidative stress involvement of these compounds, 
cardamonin-Cu(II) was found to have no effect on the intracellular GSH levels, which 
was different from cardamonin and cardamonin-Fe(II) where both compounds 
significantly depleted the intracellular GSH levels in Jurkat T cells. The findings that 
exogenous NAC, L-cysteine and GSH were not able to restore the cell viability as 
well as the unaffected intracellular GSH levels highly suggest that the cardamonin-
Cu(II)-induced cytotoxicity was not GSH dependent.  
 
 On the other hand, cardamonin-Cu(II) was found to induce oxidative stress in 
Jurkat T cells via the induction of ROS as demonstrated by the significant increase of 
intracellular ROS levels and the ability of the ROS scavenger, Trolox, to significantly 
improve cell viability of cardamonin-Cu(II) treated cells. Similar to cardamonin and 
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cardamonin-Fe(II) complex, 100 µM Z-VAD-FMK was able to attenuate cell death of 
cardamonin-Cu(II)-treated Jurkat T cells as shown in the previous chapter. Hence, the 
ability of Z-VAD-FMK to reduce intracellular ROS levels in the presence of 
cardamonin-Cu(II) further suggested that oxidative stress possibly mediated the 
apoptotic cell death of cardamonin-Cu(II)-treated Jurkat T cells via generation of 
ROS. 
 
 In spite of its initially recognised anti-oxidant property, cardamonin has been 
found to be able to work as a pro-oxidant. The ability of cardamonin to induce 
oxidative stress was recently reported by Yadav et al. (2012) where cardamonin was 
found to sensitise tumour cells to TRAIL and generate ROS in a dose dependent 
manner in HCT 116 human colon carcinoma cell line. Pre-treatment of HCT 116 with 
NAC was reported to reduce the death receptor 4 and 5 expression and reversed the 
effect of caspase-3, -8 and PARP cleavage by TRAIL-induced cardamonin. Contrary 
to the findings in this study, cardamonin has also been more often reported to act as 
an anti-oxidant agent with the ability to inhibit generation of intracellular ROS in 
RAW 264.7 macrophage cell line (Ahmad et al. 2006),  display anti-radical DPPH 
activity and ferric reducing anti-oxidant in SW-480 human colon carcinoma cells 
(Simirgiotis et al. 2008). There have also been other studies carried out to determine 
the anti-oxidant activity of cardamonin but reported its inactivity in scavenging free 
radicals and O2
•- (Mohamad et al. 2004, Li et al. 2008, Aderogba et al. 2012). 
 
 The differences in the mechanism of action suggest the presence of 
relationship between structure and oxidative stress activity. Previous studies have 
shown curcumin, another chalcone often used as cardamonin’s reference compound, 
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mediated apoptosis through modulation of the redox status of the cells via pro-oxidant 
and anti-oxidant mechanisms (Piwocka et al. 2001, Syng-Ai et al. 2004, Yoshino et 
al. 2004, Chan et al. 2005, McNally et al. 2007, Sandur et al. 2007). Pathway studies 
performed on Jurkat T cells using curcumin showing pro-oxidant activity reported the 
increase of intracellular ROS production following 60 mins of treatment with 10 µM 
curcumin and pre-treatment with NAC drastically lowered ROS production (Gopal et 
al. 2014). Similar to cardamonin, curcumin was found to deplete GSH levels, 
increased caspase-3 and -9 activity, and cleavage of PARP in Jurkat cells with 
minimal effect on normal peripheral blood mononuclear cells. In another study, low 
doses of curcumin were reported to protect hepatocytes by reducing cytochrome c 
release and lipid peroxidation while higher curcumin concentrations led to GSH 
depletion and caspase-3 activation (Ghoneim 2009) suggesting the different 
concentration of cardamonin may lead to different implications on oxidative stress. In 
a recent study, the researchers reported an interesting finding on curcumin’s 
cytotoxicity and its induction of oxidative stress (Zheng et al. 2012). Contrary to the 
findings in the present study where the cytotoxicity of cardamonin, cardamonin-
Cu(II) and cardamonin-Fe(II) were attenuated in the presence of Trolox in Jurkat T 
cells, Trolox was found to enhance curcumin’s cytotoxicity by further increasing the 
generation of ROS in A2780 human ovarian carcinoma cell line (Zheng et al. 2012). 
Curcumin’s enhanced cytotoxicity was not limited to addition of Trolox but also in 
the presence of vitamin E and vitamin C as well as in other cancer cell lines including 
MCF-7 and MDA-MB-231 human breast adenocarcinoma cell lines. These interesting 
findings highlight the possibility of cardamonin to induce different mechanisms of 
action in other cell lines. 
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 Curcumin has also been reported to induce heme oxygenase 1 (HO-1), a 
stress-response protein, through generation of ROS in human hepatoma cells where 
pre-treatment with NAC, vitamin E and catalase attenuated HO-1 induction by 
curcumin (McNally et al. 2007). Accumulating evidence demonstrated that external 
inducers such as heavy metals could induce HO-1 suggesting cardamonin and its 
metal complexes could possibly induce oxidative stress in a similar pathway. 
Furthermore, similar to cardamonin, curcumin treatment has been extensively 
reported to induce apoptosis through mitochondria-dependent pathway (Bhaumik et 
al. 1999, Morin et al. 2001, Pan et al. 2001). Previous studies have reported the 
relationship of ROS and the disruption of mitochondrial potential where excessive 
oxidative stress and ROS reaching threshold levels triggered opening of 
mitochondrial channels that led to collapse of the MMP and transient increase of ROS 
by the electron transfer chain (Zorov et al. 2006). This finding is in good agreement 
with the current study where cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
significantly increased intracellular ROS levels and studies in Chapter 5 establish the 
significant drop in MMP of treated Jurkat T cells. 
 
 Taken together, both cardamonin metal complexes, cardamonin-Cu(II) and 
cardamonin-Fe(II) demonstrated greater cytotoxicity in a dose-dependent manner 
against Jurkat T cells as shown in Chapter 5. Although there was a difference in 
Jurkat T cell susceptibility threshold against these compounds, all three compounds 
induced similar apoptotic pathway as discussed in the previous chapter. However, the 
mode of action of cardamonin-Cu(II) differed from both cardamonin and cardamonin-
Fe(II) complex in mediating oxidative stress where cardamonin and cardamonin-
Fe(II) depleted intracellular GSH and increased ROS, while cardamonin-Cu(II) 
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generated ROS without affecting intracellular GSH levels of Jurkat T cells. A recent 
study carried out to compare the pulmonary cytotoxicity of metal oxide nanoparticles, 
which include silicon oxide, ferric oxide and copper oxide nanoparticles against Hep-
2 human epithelial type 2 cells found copper oxide induced the greatest cytotoxicity 
(Fahmy and Cormier 2009). Moreover, the study found that copper oxide was even 
able to overwhelm anti-oxidant defences like glutathione reductase and catalase as 
well as increase levels of 8-isoprastane, an oxidative stress marker and lipid 
peroxidation (Morrow and Roberts 1997, Fahmy and Cormier 2009, Anestopoulos et 
al. 2016), by 1000%. This study supports the findings in the present study indicating 
there is a great degree of variability in cytotoxic effect depending on the type of 
transition metals present. Fahmy and Cormier (2009) suggested that this observed 
variation was not due to the transition metals solubility as previously postulated but 
instead was possibly due to redox cycling. Examples of redox cycling compounds 
include quinones and bleomycin that induce apoptosis by increasing intracellular 
concentration of ROS (Dypbukt et al. 1994, Hamilton et al. 1995). Stohs and Bagchi 
(1995) reviewed the oxidative mechanisms of transition metal ions in regards to ROS 
production and oxidative tissue damage. The authors highlighted the ability of metal 
ions including copper and iron to undergo redox cycling leading to production of ROS 
such as H2O2, hydroxyl radical and superoxide ion as well as the participation in 
Fenton-type reaction. Cardamonin-Cu(II) was found most cytotoxic in this study and 
exhibited a different mode of action in mediating oxidative stress. As the reduction 
potential of copper (+0.337V, Cu2+/Cu) is higher than that of iron (−0.44V, Fe2+/Fe), 
this difference could possibly account for the greater cytotoxicity induced by 
cardamonin-Cu(II). In general, copper ions cytotoxic effects have been extensively 
studied (Zhai et al. 2000, Gaetkea and Chow 2003, Qiao et al. 2011, Sarkar et al. 
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2011) and previous studies proposed copper ions induce cytotoxicity via DNA 
binding resulting in DNA damage and cell death (Aruoma et al. 1991). Another study 
reported the ability of copper ions to cause apoptotic cell death in neuronal cells by 
directly altering apoptotic genes expression (Chan et al. 2008). Furthermore, in the 
presence of Cu(II), curcumin has been reported to cause DNA strand scission, which 
was mediated by ROS (Ahsan and Hadi 1998). Other anti-oxidants have also 
demonstrated the ability to generate ROS in the presence of transition metals likes 
copper and iron ions, consistent with the findings in the current study. For instance, 
plant-derived anti-oxidants were capable of causing DNA strand breakage in the 
presence of transition metal ions including flavonoids (Rahman et al. 1989, Said et al. 
1992) and tannic acid (Bhat and Hadi 1994). Vitamin C (ascorbic acid) and uric acid, 
otherwise an anti-oxidant, acted as a pro-oxidant in the presence of iron ions (Herbert 
1990) and cleaved DNA in the presence of copper ions (Shamsi and Hadi 1995) 
respectively.  
 
 Generally, understanding the relationship between the onset of oxidative stress 
and the cellular response will be useful in understanding and elucidating the mode of 
action by which cardamonin and its metal complexes generate intracellular ROS and 
deplete GSH levels. The exact mechanism of how ROS was generated in cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II)-treated cells but only cardamonin and 
cardamonin-Fe(II) treated cells depleted GSH levels, remains unclear. It is possible 
that different metal complexes have the ability to generate diverse radicals in Jurkat T 
cells leading to different oxidative potency. Overall, this study highlights the chemical 
composition of cardamonin and its metal complexes pose a great influence on the 
biological response of exposed cells and should be further investigated.  
173 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7: CONCLUSION AND FUTURE WORK 
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7.1 General discussion and conclusion 
 
The effectiveness of cancer treatment with chemotherapeutic agents is based 
primarily on their ability to induce apoptotic cell death. The large number of articles 
published yearly on cardamonin by various researchers reflects the growing interest 
towards the subject. It is well established that cardamonin possesses diverse 
biological activities that encompass anti-inflammatory, anti-microbial, anti-oxidant, 
oxidative properties, anti-neoplastic, vasorelaxant, hypoglycaemic, anti-fungal as well 
as anti-cancer properties (Gonçalves et al. 2014). The development of natural product 
derivatives remains an important goal in enhancing the bioactivity of a compound. In 
this study, our interest has been directed to the cytotoxicity of novel semi-synthesised 
cardamonin derivatives and elucidating the mode of action of the two most active 
compounds in comparison to the parent compound, cardamonin. From a total of 20 
derivatives, the cardamonin-Cu(II) complex and cardamonin-Fe(II) complex emerged 
as valuable hit compounds exhibiting cytotoxicity 5-times and 2-times more cytotoxic 
than cardamonin in Jurkat T cells. This trend was observed across all cell lines tested 
including nasopharyngeal HK1 and lung A549 cancer cell lines where these two 
novel complexes appeared more cytotoxic than the parent compound. Since 
cardamonin-Cu(II) and cardamonin-Fe(II) were the two most cytotoxic in the 
different cell lines tested, both compounds possibly act on different targets or generate 
different effects upon binding to a specific background/ receptor compared to the 
parent compound, cardamonin. Due to scarcity of knowledge about their target(s) and 
interactions, a precise structure activity relationship is not deduced at this point. 
However, it is certain that the cytotoxicity of diverse cardamonin derivatives was 
affected by a range of factors, which include the modification of hydroxyl group, 
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presence of alkene group and addition of chemical groups, with the greatest 
cytotoxicity advantage being complexing with metal ions. Subsequent cytotoxicity 
studies found that Jurkat T cells were most susceptible towards cardamonin, 
cardamonin-Cu(II) and cardamonin-Fe(II), which prompted us to further investigate 
the possible correlation between adherent/ suspension cells and the observed 
differential susceptibility.  
 
 Previous studies have reported that suspension cells are slightly more 
susceptible to inhibition of cell growth compared to adherent cells (Kimura et al. 
2004, Daigneault et al. 2010), possibly due to the increase of some survival signals in 
adherent cells compared to suspension cells (Kohro et al. 2004). In this study, THP-1 
cell lines were used as our experimental model to assess this theory as it can be 
cultured in both suspension and adherent phase making the susceptibility studies more 
relatable and comparable considering these cells were derived from the same tissue 
origin. Indeed our results revealed cardamonin, cardamonin-Cu(II) and cardamonin-
Fe(II) complexes became less cytotoxic following THP-1-derived macrophages via 
PMA stimulation compared to the monocytes counterpart suggesting activation of 
some survival signals. To further assess our hypothesis that this change in 
susceptibility involved activation of a survival signal, namely MAP kinase known to 
be activated in PMA-stimulated cells (Huang et al. 2008), the effects of interference 
from inhibitors of p38α and p38β MAP kinase (Figure of the p38 and SB202190 
structure) on THP-1-derived macrophages were explored. Although results showed 
that the inhibition of p38 MAP kinase did not alter the cell susceptibility towards 
cardamonin and its complexes in THP-1-derived macrophages, the involvement of the 
MAP kinase pathway particularly in human acute myeloid leukaemia is definite and 
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activation of other MAP kinases should be explored including ERK and JNK protein 
kinases.  
 
 Subsequent studies were carried out to explore the cytotoxicity of cardamonin 
and its metal complexes and its underlying mechanism of action using Jurkat T cells 
as IC50 values were reported lowest in this cell line. We found that even though both 
complexes, cardamonin-Cu(II) and cardamonin-Fe(II) were more cytotoxic compared 
to cardamonin, the mode of inducing apoptotic cell death were similar. Collectively, 
our results showed that cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) 
induced apoptotic cell death that was caspase-dependent and the presence of the 
caspase-inhibitor Z-VAD-FMK was able to inhibit caspase processing and block cell 
death in Jurkat T cells. Cardamonin and both its complexes induced Jurkat T cell 
morphological changes such as cell shrinkage, DNA/ chromatic condensation, nuclear 
fragmentation, plasma membrane blebbing and formation of apoptotic bodies, all of 
which were typical of apoptosis. There were no enlargement/ swelling of cells 
observed morphologically, which further confirms cell death was apoptotic rather 
than necrotic. Furthermore, the exposure of PS and collapse of the MMP indicate that 
both these compounds could be promising anti-cancer agents as inducers of apoptotic 
cell death. As the Z-VAD-FMK caspase inhibitor was able to block cell death induced 
by cardamonin and its two complexes, caspase activation was analysed in the 
presence or absence of Z-VAD-FMK. All three compounds activated caspase-9 and 
caspase-3 as well as PARP-1, a caspase-3 substrate, which was cleaved from p116 to 
the signature p85 fragment. Modification of this protein is known to occur in response 
to DNA damage. Caspase-8 however was not activated suggesting cardamonin and its 
two complexes induced apoptosis via the intrinsic mitochondrial pathway. In the 
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presence of Z-VAD-FMK, the processing of caspase-3, -9 and the cleavage of PARP-
1 by cardamonin and its complexes was completely abrogated confirming this cell 
death pathway is indeed a caspase-dependent process.  
 
 As previous studies have reported the ability of metals to induce apoptosis 
through oxidative stress, in the final chapter of this study, we investigated the effects 
of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) on Jurkat T cells’ oxidative 
state. Results revealed oxidative stress caused by the depletion of intracellular GSH 
and production of ROS was involved in cardamonin and cardamonin-Fe(II)-induced 
Jurkat T cell death. Cardamonin-Cu(II) however did not significantly affect 
intracellular GSH levels but generated the production of ROS. The presence of NAC, 
L-cysteine and GSH was able to significantly increase cell viability of cardamonin 
and cardamonin-Fe(II)-induced Jurkat T cell death but had no significant effect on 
cardamonin-Cu(II)-treated cells. Trolox, the ROS scavenger, was the only anti-
oxidant to significantly improve cell viability of cardamonin-Cu(II) treated cells 
suggesting cardamonin-Cu(II)-induced cytotoxicity via generation of ROS. 
Interestingly, in the presence of Z-VAD-FMK the intracellular GSH and ROS levels 
significantly increased and decreased, respectively from the cells with cardamonin- 
and cardamonin-Fe(II)-treatment alone. The ROS levels significantly decreased in 
cardamonin-Cu(II)-treated Jurkat T cells in the presence of Z-VAD-FMK. These 
findings further suggest that oxidative stress potentially mediated the apoptotic cell 
death of cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II)-treated Jurkat T cells. 
It is important to note that this is the first notable difference observed in the 
mechanism of action between complex cardamonin-Cu(II) and parent compound, 
cardamonin. This difference in bioactivity is further substantiated as copper ions are 
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known to undergo redox cycling that leads to production of ROS and studies have 
reported the ability of copper oxide to induce great cytotoxicity and overwhelm anti-
oxidant defences like glutathione reductase and catalase (Morrow and Roberts 1997, 
Fahmy and Cormier 2009, Anestopoulos et al. 2016, Deo et al. 2016). Hence, this 
study truly highlights the degree of variability in cytotoxicity and the extent of 
cytotoxicity depending on the type of transition metal that is complexed to the lead 
compound. It is possible that different metal complexes have the ability to generate 
diverse radicals in Jurkat T cells leading to the observed different oxidative potency 
seen in this study. Overall, oxidative stress analysis suggested that ROS played a 
more vital role in cardamonin-Cu(II)-induced cytotoxicity in Jurkat T cells compared 
to GSH. As these free radicals are known to be typically generated from the 
mitochondria, cardamonin and its complexes are proposed to target the mitochondria 
pathway mediated by oxidative stress via production of ROS, subsequently triggering 
the intrinsic mitochondrial apoptotic pathway as summarised in Figure 7.1. Taken 
together, these findings highlight the potential of cardamonin-Cu(II) and cardamonin-
Fe(II) complexes as promising candidates of novel cardamonin-based derivatives for 
the development of anti-tumour therapies, particularly for targeting leukaemia. 
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Figure 7.1 Proposed model of cardamonin-, cardamonin-Cu(II) and 
cardamonin-Fe(II)-induced apoptosis in Jurkat T cells. 
Cardamonin, cardamonin-Cu(II) and cardamonin-(Fe) is proposed to target the cell 
mitochondria leading to generation of intracellular ROS and the depletion of 
intracellular GSH (only observed in cardamonin and cardamonin-Fe(II)-treated Jurkat 
T cells). Subsequently, the mitochondria mediated intrinsic apoptotic pathway elicit 
the collapse of mitochondria membrane potential and externalisation of 
phosphatidylserine with caspase-9 activation that is followed by activation of 
downstream executioner caspase-3 and cleavage of PARP-1, the downstream 
substrate of caspase-3. DNA condensation and fragmentation into apoptotic bodies 
were observed morphologically. The caspase inhibitor, Z-VAD-FMK, readily blocks 
this caspase-dependent apoptotic pathway. Intracellular ROS and GSH levels were 
recovered close to levels of untreated Jurkat T cells in the presence of Z-VAD-FMK. 
Furthermore, anti-oxidants NAC, L-cysteine, GSH and Trolox significantly increased 
cell viability in cardamonin and cardamonin-Fe(II)-treated cells whereas the radical 
scavenger, Trolox, was the only anti-oxidant capable of increasing cell viability in 
cardamonin-Cu(II)-treated cells. This study demonstrates cardamonin and its metal 
complexes, cardamonin-Cu(II) and cardamonin-Fe(II), induced apoptotic cell death in 
Jurkat T cells via an oxidative stress mediated caspase-dependent pathway. *indicates 
no effect in cardamonin-Cu(II)-treated Jurkat T cells. 
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7.2 Future work  
 
Data presented in this study thus far suggest that cardamonin, cardamonin-Cu(II) and 
cardamonin-Fe(II) induced apoptosis in Jurkat T cells by generating intracellular ROS 
and depleting intracellular GSH levels (only in cardamonin and cardamonin-Fe(II)-
treated cells). Following on from the work presented in Chapter 3, it would be 
interesting to study the effect of these three compounds on normal peripheral blood 
mononuclear cells. Determining the cytotoxicity of these compounds against normal 
peripheral blood cells is important for their potential use in treating blood related 
disorders. Furthermore, initial screening of cardamonin and its derivatives reveals 
complexing cardamonin with metal ions offer the greatest cytotoxicity advantage. 
Hence, future studies should focus on complexing cardamonin to other metal ions 
particularly transition metal intercalators like platinum, ruthenium, nickel and gold, 
which are highly biologically active with exceptional versatility (Deo et al. 2016). 
Additionally, an iodine-derived-metal complex should be semi-synthesised and 
assessed for cytotoxicity since iodination of cardamonin has been shown to improve 
the cytotoxic activity. In Chapter 4, inhibition of p38 MAP kinase did not alter cell 
susceptibility in treated THP-1-derived macrophages suggesting p38α and p38β MAP 
kinase may not be mainly responsible for the increase in cell resistance. Subsequent 
studies should determine the involvement of other MAP kinase pathway such as ERK 
and JNK protein kinase activation. Determining the protein kinase involved is 
important in elucidating the mode of action observed from increased resistance in 
matured macrophages compared to monocytes. This chapter also highlighted the 
novel use of cardamonin and its complexes as potential anti-leukemia agent that was 
more effective against immature leukaemic cells than mature cells. Therefore, apart 
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from Jurkat T leukaemic lymphoblast cell, other leukaemic cell lines should be tested 
against cardamonin, cardamonin-Cu(II) and cardamonin-Fe(II) such as HL60 
promyelocytic leukaemia and K562 chronic myelogenous leukaemia cell line. In an 
effort to elucidate the mechanism of cytotoxicity exerted by cardamonin and its 
complexes, we established that these compounds induced apoptosis in Jurkat T cells 
via the intrinsic mitochondrial pathway activating caspase-9 and -3. Additional 
studies into cell cycle analysis to determine the stages of cell cycle arrest (G0/G1, G1, 
S and G2/M) induced by these compounds are desirable. Furthermore, apoptotic 
mitochondrial events are known to occur through B cell lymphoma-2 (BCL-2) family 
of proteins, which govern mitochondrial membrane permeability (Cory and Adams 
2002). Based on current findings, cardamonin and its complexes activate the 
mitochondria pathway to induce apoptosis, substantiating the need for further 
investigations on the regulation of BCL-2 proteins such as pro-apoptotic proteins 
(BCL-10, BAX, BAK, BID, BAD, BIM, BIK, and BLK) and anti-apoptotic proteins 
(BCL-2, BCL-X, BCL-XL, BCL-XS, BCL-W, BAG) (Elmore 2007, Roy et al. 2014). 
Since cardamonin and both its complexes were found to induce oxidative stress in 
Jurkat T cells, future studies can also include an investigation on detecting the 
different species of ROS generated including effect on the mitochondrial transport 
chain to further elucidate how these compounds generate ROS in these cells. 
Additionally, studies can be carried out in cell-free systems to detect the possible anti-
oxidant/ pro-oxidant capacity of cardamonin, cardamonin-Cu(II) and cardamonin-
Fe(II). Ultimately, these accompanying studies are suggested to further our 
understanding in the roles of oxidative stress-mediated apoptosis, which may be 
beneficial for future development of these compounds as potential anti-cancer agents.  
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